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Deutsche Zusammenfassung 
 
1.1 Einleitung und Zielsetzung 
 
Juvenile Idiopathische Arthritis ist ein Begriff, der verwendet wird, um eine 
heterogene Gruppe von Erkrankungen unbekannter Ätiologie, gekennzeichnet 
durch eine chronische Arthritis  bei Kindern unter 16 Jahren zu beschreiben 
(Petty et al., 2004). JIA ist die häufigste chronisch entzündlich rheumatische 
Erkrankung im Kindesalter (Weis und Ilowite, 2007). 
 
Die  Diagnose  Juvenile  Idiopathische  Arthritis  steht  für  eine  chronische,  
mindestens  6  Wochen  persistierende   Arthritis  mit  einem  Erkrankungsbeginn  
im  Alter von unter 16  Jahren  bei  Ausschluss  anderer  Ursachen.  Betroffene  
leiden  unter  schmerzhaften  Schwellungen,  Ergüssen,  Druckempfindlichkeit  
und  Bewegungseinschränkungen der Gelenke. 
 
Um eine  irreversible  Schädigung  der  Gelenke  zu  vermeiden, ist  deshalb  
eine frühzeitige  und  effektive  Therapie  wichtig.  Methotrexat  ist  derzeit  am  
häufigsten eingesetzte Langzeitantirheumatikum. Methotrexat wird als „first 
choice secondline agent“ für die JIA bezeichnet (Miller und Cassidy, 2007). 
 
Ziel der Behandlung der JIA ist die Remission, um den Kindern eine 
altersgerechte Entwicklung ohne Schmerzen und Funktionseinschränkung zu 
ermöglichen. 
 
Einige Patienten brechen die Therapie mit MTX wegen Unverträglichkeiten ab. 
Eine Vorhersage des Ansprechen auf MTX könnte helfen, eine Therapie mit 
Biologika sobald wie möglich zu starten, und  irreversible Komplikationen zu 
verhindern. 
 
Das Ziel der Studie ist es, festzustellen, ob demographische, klinische und 
labormedizinische Variablen das Ansprechen auf MTX vorhersagen können. 
 
1.2  Material und Methoden 
 
Das Patientenkollektiv wurde dem deutsche BIKER-Register entnommen. 
Gegründet im Jahre 2001, enthielt es zum Stichtag der Untersuchung, dem 
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31.12.2010, 1063 Patienten, die nach einem bestimmten Rhythmus dokumentiert 
wurden. 915  Patienten erfüllten alle Ein- und Ausschlusskriterien. 
Einschlusskriterien waren:   
- die Diagnose einer JIA nach den ILAR-Kriterien 
- eine begonnene Therapie mit MTX 
- Therapiedauer  (mit MTX) von mindestens 3 Monaten 
 
Ausschlusskriterium war eine  Therapie mit einem Biologikum. 
 
 
 
Um  das Ausmaß der Verbesserung  abzuschätzen,  wurde  der  PedACR- Score 
verwendet.  Nach  diesen Kriterien  müssen  die Kinder eine  Verbesserung  von 
mindestens 30 % (PedACR 30), oder 70% (PedACR 70)in  mindestens drei  der 
sechs folgenden Variablen haben: Anzahl bewegungseingeschränkter Gelenke, 
Anzahl aktiver Gelenke, Patienten-VAS zur Globalen  Beeinträchtigung,  Arzt-
VAS zur Globalen Krankheitsaktivität, CHAQ und BSG. Eine  Verschlechterung  
von  bis  zu 30 % darf  in  nicht  mehr als  einem  Parameter  auftreten.  Die 
Bewertung erfolgte 3, 6 und 12 Monaten nach dem Therapiestart. 
 
 
Bei  den  verwendeten  Daten  handelt  es  sich um  Daten aus einem laufenden  
Register, welches  in  einer  Microsoft  Access  Datenbank vorliegt.  Die  Auswer- 
tung  wurde mit SPSS (Version 21) durchgeführt. Als Verfahren  der  deskriptiven 
Statistik wurden bei kontinuierlichen Daten Mittelwerte, Median, Standard- 
abweichung,  Minimal und  Maximalwert und  bei  Kategorien  Daten (Prozente) 
Häufigkeiten  verwendet.  Statistische  Tests  beinhalteten  den  Korrelationstest 
nach  Pearson oder Spearman, den Odds Ratios (OR)  mit (confidence  Interval) 
und AUC (Area Under the Reciever Operating Curve). 
 
1.3  Ergebnisse 
 
 
Das Ansprechen auf MTX nach PedACR 70- Kriterien zeigte in der multivariablen 
Analyse der logistischen Regressionsanalyse eine signifikante Assoziation mit 
der folgenden Parametern: 
 
 
- Nach 3 Monaten: eine größere Anzahl von Gelenken mit einem eingesch-  
ränkten Bewegungsumfang (p=0.004) und eine höhere Punktzahl im Arzt- 
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VAS (p=0.004). 
 
- nach 6 Monaten: Krankheitsdauer < 1 Jahr (p< 0.001), ein niedriges Alter 
bei Beginn der Therapie mit MTX (p= 0.018), eine höhere Punktzahl im 
Arzt-VAS (p= 0.004) und eine größere Anzahl von geschwollenen 
Gelenken (p= 0.001). 
 
 
- nach 12 Monaten: Krankheitsdauer< 1 Jahr (p= 0.001), ein niedriges Alter 
bei Beginn der Therapie mit MTX (p< 0.001), eine größere Anzahl von 
aktiven Gelenken (p< 0.001), eine geringere Anzahl von Gelenken mit 
Schmerzen (p= 0.004), ein erhöhtes CRP (p= 0.018), eine höhere 
Punktzahl bei der  Schmerzbeurteilung durch die Eltern (p= 0.037) und die 
Präsenz der Morgensteifigkeit (p= 0.016). 
 
1.4 Diskussion    
 
Das  Ansprechen  auf  MTX  nach PedACR 70- Kriterien   war  negativ  assoziiert  
mit einer  geringeren  Anzahl  von  Gelenken  mit  einem  eingeschränkten   
Bewegungsumfang, einer niedrigeren  Punktzahl  von  Arzt-VAS, Krankheits- 
dauer >1 Jahr,  einem  höheren  Alter  bei  Anfang  der Therapie  mit  MTX,  
einer geringeren Anzahl von aktiven Gelenken, einer größeren Anzahl von 
Gelenken mit  Schmerzen, niedrigeren CRP Werten, einer niedrigeren Punktzahl 
 bei der Schmerzbeurteilung durch die Eltern und die Abwesenheit einer 
Morgensteifigkeit.  
 
Die  diagnostische  Zuverlässigkeit   wurde  anhand    der  ROC  Kurve  (receiver 
characterstics  curve)  bestimmt.  Die   beste  diagnostische  Genauigkeit   wurde   
gemäß   PedACR 30   nach  3  Monaten  (AUROC= 0.73 ,  Sensitivität=  98.9 % ,  
Spezifität=  10.7 %)  und   laut  PedACR 70  nach 12   Monaten ( AUROC= 0.69 ,  
Sensitivität= 91.5 % , Spezifität= 33.2 %) erreicht. 
 
Die Ergebnisse dieser Studie können als  Empfehlung zum Einsatz von MTX bei 
JIA angesehen werden, da  die hier  gefunden Faktoren negative Prädiktoren für 
ein Ansprechen auf MTX, auch nach Therapie von bis  zu 12 Monaten, darstellen 
und dadurch die Entscheidung, eine alternative Therapie zu beginnen erleichtern. 
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2.  Introduction and objectives    
2.1  Introduction 
Juvenile idiopathic arthritis is an umbrella term used to describe a heterogeneous 
group of disorders of unknown etiology, characterized by chronic arthritis 
affecting children below 16 years (Petty et al., 2004).   Juvenile idiopathic arthritis 
is the most chronic rheumatic illness in children and it is responsible for short and 
long-term disability (Weis  and Ilowite, 2007).  
 In the recent years an increased number of disease-modifying anti-rheumatic   
drugs (DMARDs) have been developed for treatment of juvenile idiopathic  
arthritis,  but methotrexate still the most common  second line  therapeutic  agent  
used  in  treatment  of juvenile idiopathic arthritis worldwide (Miller  and Cassidy, 
2007), however, there is variation in the clinical response to methotrexate  among  
the   patients. Prediction of response can prevent   further exposing of patients to 
side effects of methotrexate and also saving the time by progressing to the 
treatment with biologics as soon as possible to prevent irreversible complications.  
This is a retrospective study of 915 patients with juvenile idiopathic arthritis. The 
cohort of patients was collected from the German Methotrexate registry. The 
analysis of demographic, clinical, articular and laboratory characteristics of   the  
patients was made at  baseline and during follow up at month 3, 6 and 12. The 
improvement was assessed according to the paediatric criteria of American 
College of Rheumatology by using PedACR 30 for minimal improvement analysis 
and PedACR 70 for strong improvement analysis.   
2.2  Juvenile Idiopathic Arthritis 
Traditionally, this term was used to describe chronic arthritis persisting for at least 
6 weeks  in  an individual 16  years  of  age or  younger  after  exclusion  of  other 
reasons of arthritis (Miller  and Cassidy, 2007).                                                        
Juvenile idiopathic arthritis is the most common chronic rheumatic illness in 
children and is a significant cause of short and long term disability (Weis and 
Ilowite, 2007).                                                                                                 
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2.2.1  Epidemiology                                                                         
There are differences in estimates for the prevalence and incidence of JIA. These 
differences occurred due to many factors, which include development of new 
diagnostic criteria, in addition to the differing of definitions of clinical cases and to 
the factors occurring with the passage of time, for examples; standards of living, 
health care resources and increasing knowledge.                                                    
In one study by Manners and Bower in 2002 a review of 34 epidemiological 
studies of JIA since 1966 was undertaken, the results shows that  the prevalence 
of JIA is reported as 7-401 per 100.000 children, and the annual incidence is 
reported as 0.8-22.6 per 100.000 children (Manners and Bower, 2002).                
                                                                                                    
2.2.2  Classification of Juvenile idiopathic arthritis                                                   
The classification of juvenile idiopathic arthritis according specific criteria in many 
subtypes allows better understanding of their pathogenesis and clinical course. 
Many of the recent studies on pathogenesis have simply divided patients in  three 
main categories:  oligoarthritis, polyarthritis and systemic arthritis.                          
In the fact there are different classifications for juvenile idiopathic arthritis, but in 
our  study  we used  the  classification  according ILAR  (International League of 
Association  for  Rheumatology)   congress  2001,  in  which  juvenile  idiopathic 
arthritis divided in seven categories:                                                                        
Type 1   systemic onset juvenile arthritis (formerly called Still's disease) 
Type 2    seronegative polyarthritis (at least 5 joints affected during first 6 months 
and RF is negative)                                                                                                  
Type 3   seropositive polyarthritis (at least 5  joints affected during first 6  months 
and RF is positive) 
Type 4a  persistent oligoarthritis  (less than 5 joints affected )  
Type 4b  extended  oligoarthritis  (5  or   more  joints  become  affected  after  6 
months) 
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Type 5   Enthesitis related arthritis (ERA) 
Type 6   Psoriasis related arthritis (JPsA) 
Type 7   unclassified arthritis (matching  no or more than 2 categories) 
According the frequency of each subtype, the oligoarticular JIA is the most 
common (50-60 %), then polyarticular JIA (30-35 %), SoJIA (10-20 %), JPsA (2-
15 %), and  ERA (1-7 %).                                                                                          
The categories are recognised based on the clinical features during the first 6 
months of the disease (Table 1). Important clinical features that assist in 
classifying patients  include the presence of enthesitis (inflammation at the sites 
of attachment of ligament, tendon, or fascia  to  bone),  dactylitis,  inflammatory  
lumbosacral pain, nail  pitting, sacroiliitis, fever,  rash,  and  serositis.                     
Juvenile idiopathic  arthritis  is diagnosed  when  arthritis occurs before  sixteenth 
birthday and has been presented for  at  least  6  weeks  with  no other  apparent 
diagnosis. The arthritis may be unclassified between 6 weeks and 6 months, after 
which time it can be categorized in one of seven subtypes.                                    
*Separate  diagnostic  disease,  ACR=  American  College  of   Rheumatology,   ILAR=   
 International  League  of  Associations  for  Rheumatology,   RF=  Rheumatoid  Factor 
(Passo and Rosen, 2005) 
Table  1: Comparison of  the ILAR and  ACR,  the criteria and the associated systemic 
manifestations                                                                                                    
Systemic feature ILAR classification ACR classification 
Fever, rash, pericarditis, 
hemophagocytic syndrome  
systemic arthritis Systemic  
Uveitis Oligoarthritis 
(persistent) 
Pauciarticular (early onset) 
Uveitis Extened oligoarthritis   
Low grade fever, uveitis Polyarthritis, RF-ve Polyarticular, seronegative 
Nodules, Felty syndrome, 
Sjögren syndrome 
Polyarthritis, RF+ve Polyarticular, seropositive 
Spondylitis, acute iritis and 
inflammatory bowel disease 
Enthesitis related Pauciarticular (late onset) 
Psoriasis and uveitis 
 
Psoriatic arthritis Psoriatic arthritis* 
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Systemic arthritis                                                                                                       
Systemic  arthritis  is the less  common  subtype, and  usually  begins  with  high, 
spiking fevers  to greater  than  39.4 ᵒC, the fever  frequently is  accompanied  by 
rash that comes and  goes with  temperature elevations.  Joint  involvement  may 
occur either at onset or later in the course  of the disease.                                     
                                                       
Oligoarthritis    
Oligoarthritis category of JIA affects four or fewer joints in the first six months of 
disease. If more than four joints become involved after six months, it is defined as 
extended oligoarthritis, otherwise it is classified as persisting oligoarthritis.  
Oligoarthritis  is the most common form of JIA, and preferentially afflicts 1 to 3 
years old caucasian girls.                                                                                          
Although all races can be affected, the prevalence is much reduced in non 
caucasians. Girls outnumber boys 4:1, clinically about half  of oligoarticular JIA 
patient will have a single joint involved at onset, mainly the knee. The next most 
commonly affected joints  is the ankle, and the small joints of the hand are the 
third most commonly affected. Wrist involvement  is rare and may indicate  the 
progression to extended oligoarthritis. Up to 20 % of patients can develop uveitis, 
which usually asymptomatic and it is more prevalent in the children, who are ANA 
positive. (Woo  et al., 2007).                                                                                     
                                                            
Polyarthritis 
In both polyarthritis categories there are five or  more  joints involved in the first 
six months, girls outnumber boys in both categories, seronegative subtype is 
more common than seropositive.                                                                              
Polyarthritis subtypes characteristically involves the small joints of the hands and 
feet, but large joints involvement is also common.                                                    
Approximately one fourth of the seronegative   polyarthritis  patients have positive 
test results for ANA, and few of the  patients have associated chronic uveitis. The  
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onset of illness usually occurs when the child is 10 years old or younger. 
In general, seronegative  JIA patients  respond  better  to treatment  with NSAIDs 
than  do  seropositive  patients. Only  about  5-8 %  of  all  children  with   chronic 
arthritis are  seropositive  for  rheumatoid factor. The onset of  this illness  usually 
occurs when the child is 9-16 years of age (Miller  and Cassidy, 2007).                 
                                                                                                                                        
Enthesitis Related Arthritis 
Enthesitis related arthritis is defined as arthritis and/or enthesitis (inflammation of 
tendons or ligaments where they attach to bone ) with at least two of the following 
features: (1) Sacroiliac joint tenderness, or inflammatory lumbosacral pain  (2) 
HLA-B27 positive (3) First degree relative with medically confirmed HLA-B27 
associated disease (4) Uveitis (5) Onset of arthritis in a boy six years or older. 
Enthesitis related arthritis  is more frequent in boys (Burgos-varagas et al., 1997). 
The onset typically occurs in children over six and there is a familial predilection.   
 
                                          
Psoriatic Arthritis 
Juvenile psoriatic arthritis is chronic inflammatory arthritis with a peak  age of 
onset in mid childhood.  Juvenile  psoriatic  arthritis  is  difficult   to be diagnosed, 
because the arthritis may develop many years before the skin manifestation. 
JPsA is an asymmetric arthritis that often affects the knees, and  the ankles,  and 
the small  joints   of   the  hands   and  feet.  Proximal interphalangeal joints, and  
tendon sheath are  often  inflamed,  resulting in the  diffuse  swelling  of  the digit 
known  as  sausage  digit (Shore, 1982). Extra-articular manifestations include 
rash, nail changes (including pitting, onycholysis, oil drop sign ), and  uveitis. One 
third of patients with JPsA develop the psoriasis  by 15  years  of  age (Petty and 
Malleson, 1986).                                                                                                        
All children with JPsA should have a slit-lamp examination at least every 6 
months, because asymptomatic anterior uveitis may be found in up 17 % of 
patients.                                                                                                                     
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Laboratory data show elevated acute phase reactants, anemia of chronic 
disease, and thrombocytosis. Also ANA may be positive (Southwood and Petty, 
1989)                                                                                                                           
2.2.3  Etiology and Pathology 
The causes of juvenile idiopathic arthritis remain unclear, but it seems to be a 
complex genetic trait  involving  the  effects of multiple genes  related to immunity 
and inflammation. Some hypothesize that arthritis may be triggered in a 
genetically  predisposed  individual by psychologic  stress, abnormal  hormone 
levels, trauma  to a joint,  or bacterial or viral infection. Several  studies  have   
implicated rubella  and  parvovirus  B19  as  possible causes of JIA because 
rubella virus persists in lymphocytes and  establishes  a focus  of  persistent   
infection in  the synovium   resulting   in  chronic inflammation (Lang and  Shore, 
1990).                                                                                                                        
Certain HLA class 1 and class 2 alleles are associated with an increased risk of 
JIA. The class 1 antigen HLA-A2 is associated with early onset oligoarthritis in 
girls (Murray KJ, et al, 1998).  The class 2 antigens HLA-DRB1*08 and *11, 
DQA1*04 and *05, and DQB1*04 are associated with persistent oligoarticular and 
extended oligoarticular JIA. HLA-DRB1*08 confers an increased risk of 
rheumatoid factor (RF) negative polyarthritis, and HLA-DRB1*11 confers an 
increased risk of systemic onset JIA (SOJIA). HLAB1*04, which associated with 
adult rheumatoid arthritis, is associated with an increased risk of RF positive 
polyarticular arthritis. The class 1 antigen HLA-B27 and class 2 antigens HLA-
DRB1*01 and DQA1*0101 are associated with enthesitis related arthritis (ERA) 
and JPsA. Other genes conferring risk include cytokine production regulating 
genes. Anti-nuclear antibodies (ANA) are found in approximately 40 % of patients 
with JIA, especially in young girls with oligoarticular disease (Petty RE, Cassidy 
JT, Sullivan DB, 1973). Approximately 5 % to 8 % of patients with JIA are 
rheumatoid factor positive (Lang BA, Shore A, 1990). The T-lymphocytes 
mediated immune response is involved in chronic inflammation, and T cells are 
the predominant    mononuclear cells in synovial fluid.                                             
Patients with JIA have  elevated serum levels of interleukin (IL) -1,-2,-6, and IL-2  
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receptor (R), and elevated synovial fluid levels of IL-1B,  IL-6 and IL-2R, 
suggesting a Th1 profile. Elevated serum levels of IL-6, IL-2R, and soluble  tumor 
necrosis  factor (TNF) receptor  correlate with inflammatory  parameters, such as 
C-reactive  protein,  in JIA  patients  indicate active disease.  Serum levels  of IL-
6 are increased in SoJIA and rise before each fever spike, correlating with active 
disease and elevation of acute phase reactants (Weis and Ilowite, 2007).             
                                                                               
2.2.4 Prognosis  
The prognosis of JIA in an individual child is so far unpredictable. Studies from 
United States indicate that despite the current management,  approximately 45 % 
of JIA patients have active disease persisting into early adulthood, often with 
severe  limitation  of physical  function (Miller  and Cassidy, 2007).                         
Most children with oligoarthritis do well, in about 20-30 % of these children 
oligoarthritis becomes extended and the outcome is  poor  until    methotrexate is 
introduced as the treatment   of choice. Remission is induced in 60-70 % while on 
methotrexate. Anti-TNF agents are effective if patients fail to respond to 
methotrexate, especially if given in combination with methotrexate (Woo P et al., 
2007).                                                                                                                        
The child with oligoarticular disease, particularly  a girl  with  early  onset  of 
arthritis  at < 6  years  of  age is at risk  to develop  chronic  uveitis.  There  is 
usually no  association  in the  course  of   the  arthritis  and  chronic  uveitis. 
Uveitis can  result  in  posterior synechiae, untreated  or  refractory  disease can 
result  in  blindness, which  can be  decreased  by  frequent  monitoring with slit-
lamp examination to exclude asymptomatic uveitis (Miller  and Cassidy, 2007).     
Other sequelae include leg length discrepancy, especially in those with knee 
arthritis. Muscle atrophy can occur due to persistent swelling and pain.  The child 
 with polyarticular disease often has a more prolonged course. Poor prognosis  
associated with older age of onset, the presence of rheumatoid factor  seropos- 
itivity  or  rheumatoid  nodules,  or  the early  involvement of cervical spine or hips 
(Miller  and Cassidy, 2007).                                                                                      
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The child with systemic JIA onset is often the most difficult to manage  in terms of 
both  articular and systemic manifestations. However systemic manifestations are 
usually  present  only  during  the first  few years  after onset. The prognosis after 
that time dependent on  the  number of the joints involved and severity of arthritis 
(Miller  and Cassidy, 2007).                                                                                      
The long term outcome of enthesitis related arthritis is poorly described,  
enthesitis  is more  symptomatic  in   teens  and   young  adults, and it improves 
with age. Boys with HLA-B27 and hip arthritis, or tarsitis are at high risk of 
developing progressive spinal involvement. Children with psoriatic arthritis  tend 
to have longer lasting disease, and small but significant percentage  (up to 10 %) 
may be disabled (Woo  et al., 2007).                                                                        
 
2.2.5  Treatment of Juvenile Idiopathic Arthritis       
The objectives of treatment include controlling pain  and inflammation, preserving 
function, and promoting normal growth, overall development, and wellbeing as 
well as to achieve these goals with minimal risk of side effects. The long term 
treatment of children with JIA is initiated and subsequently modified according to 
disease sub-type, severity of the disease, specific manifestation of the illness and 
the response to  therapy (Miller and Cassidy, 2007).                                                
Therapy is directed toward the underlying inflammation of JIA (e.g. joint damage). 
Medication include first line NSAIDs and second line drugs that include 
immunomodulators, biologic agents, corticosteroids and gold. Initial drug therapy 
for children with polyarticular juvenile idiopathic arthritis  should be aggressive in 
order to control the inflammatory  process and  relieve  symptoms  as  quickly as 
possible while  minimizing  drug  side  effects (Lachman, 2007). Treatment 
usually started with the least toxic medication usually NSAID, and proceeding 
through  methotrexate to modulatory biologics. Medications that place the child 's 
present and future health most at risk, such as azathioprine, and cyclophos- 
phamide, are reserved for the very few children who do not respond  to less 
aggressive  therapy.                                                                                                  
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NSAIDs traditionally have been the preferred first line drugs, these medications 
reach full efficacy within two to three months, but usually start to relieve 
symptoms within a few days. The improvement will be clear in most of the 
patients within the first three months (Ruperto et al., 2005).                                     
Systemic corticosteroids are very powerful anti-inflammatory medications, but 
their use is limited, because the risk of side effects, which include Cushing’s 
syndrome, hyperglycemia, immunosuppression, cataract, glaucoma, peptic ulcer, 
osteopenia, and growth retardation. Although glucocorticosteroids are the 
mainstay of treatment for controlling serious systemic manifestations of systemic 
JIA, use in polyarthritis  patients should be limited as bridging agent to patients  
with extreme pain, disabling morning stiffness  and functional limitation while 
waiting for a second – line agent to show  some effect (Klein and Horneff, 2009). 
However short term use of low dose  corticosteroids (less than o.25 mg /kg per 
day of prednisolone or it 's equivalent) may provide substantial benefits without 
complication, so we can say that the use of glucocorticosteroids like bridge  
between the NSAIDs and other DMARDs.                                                               
Intra- articular injections of corticosteroids is an effective therapy for patients with 
JIA,  and  majority of patients having  complete and long  lasting response (Srini- 
-vasan  et al., 2012). Triamcinolone hexacetonide (10-40 mg/joint or 1-2 mg/ kg/ 
joint) is commonly used and has been shown to result in improvement of signs 
and symptoms of arthritis. The side effects may include infection, atrophic skin 
changes at the site of injection, and asymptomatic calcifications on radiographs.   
 
Disease modifying antirheumatic agents 
DMARDs are a group of drugs which effective in treatment of JIA e.g. sulfasalaz- 
ine, methotrexate and leflunomide.                                                                            
 Methotrexate                       
MTX is the most common used as a second line treatment of JIA and it will be 
discussed in details  in section 1.3 .                                                                          
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Leflunomide 
Leflunomide  is an immunomodulator that inhibits  pyrimidine  synthesis, it has  
been  shown  to  be  safe  and   effective  in   adults   with   rheumatoid arthritis, 
and has also been  studied for use in JIA. Preliminary results  show efficacy  
similar to  that  of methotrexate,  but  has  not  been  shown  to  be superior  to  
methotrexate   (Silverman  et al., 2005a, 2005b).                                                     
Side effects of leflunomide   include   diarrhea, elevated liver  enzymes,  mucocu- 
-taneous  abnormalities  and teratogenicity (Weiss and Ilowite, 2007).                   
                                                      
Sulfasalazine 
Sulfasalazine has been shown  to be beneficial  for  many children with enthesitis 
related  arthritis, families  must be warned  of  the  possible  development  of  
rare severe reactions seen with sulfa drugs e.g  Stevens-Johnson  syndrome. 
Sulfasalazine  does  not  prevent  chronic  changes  and   therefore  should   not 
be relied upon in erosive disease (Lachman,  2007).                                               
Other  immunomodulators  like azathioprine  and  cyclosporine  have been used  
with varying success  in the past. Currently   they are not preferred for treatment 
because  of their significant  potential  toxicity, and they  are  less effective  than  
the newer biologic  agents  (Klein  and Horneff, 2009).                                            
                                                                                
Biologic agents                                                                             
They are group of agents, include the TNF inhibitors etanercept, infliximab, 
adalimumab, golimumab and certolizumab, the IL-1 inhibitor anakinra,   
rilonacept  and   canacinumab, the  IL-6 receptor blocker  tocilizumab  and  the B-
cell  depleter rituximab, they  are  currently  being used in  patients  with RA  and 
JIA resistant to  methotrexate.                                                                                  
All biologic  agents carry a risk of immunosuppression,  infection,   and  possibly  
malignancies. Live  virus   vaccines   are  relatively   contraindicated.  Cases   of  
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 reactivated  tuberculosis   have  been   reported   in  JIA  patients  using  the 
TNF inhibitors  (Weiss and Ilowite, 2007).                                                               
        
Etanercept                                                                                  
Etanercept  is  a fusion  protein  containing  tumor  necrosis factor (TNF) receptor 
and FC fragment from human IgG. It is effective  in  many  children  with resistant 
 polyarthritis   disease  (Horneff   et al., 2004; Lovell et al., 2000).                           
Patients treated with etanercept show  dramatic   improvements   within    weeks 
of starting therapy, with benefits  persisting  for  years. Etanercept   was  proven 
effective in controlling pain and swelling and in improving laboratory   parameters 
 (Lovell  et al., 2003, 2006, 2008).                                                                             
Approximately  three  fourths  of  patients  who  do not respond  adequately   to 
methotrexate  will  have a good  response to etanercept.  Etanercept  0.4 mg /kg 
(maximum 25 mg)  given subcutaneously twice weekly has  a dramatic response, 
and is highly recommended for patients with extended oligoarthritis or   
polyarthritis   who  have   not responded to  NSAIDs   and  methotrexate.               
In addition  there  is increasing  evidence  from  the studies that the  combination 
of  etanercept  and  methotrexate in  synergistic  was   well   tolerated and  highly 
effective especially in treatment of  juvenile  polyarthritis  but  not  in patients  with 
systemic arthritis (Schmeling  et al., 2001).                                                             
            
                                             Infliximab  
Infliximab  is  a chimeric   mouse-human   monoclonal   anti-TNF-alpha  antibody. 
Infliximab may have similar efficacy to that seen  with  the use  of etanercept,  but 
the incidence of adverse  effects  was  higher  and  more serious in  the infliximab 
group  than  in  etanercept  group.  A short  term head to head placebo controlled 
study  in  juvenile   idiopathic   arthritis patients has  shown that  infliximab  failed 
to reach  the primary  end point (Ruperto  et al., 2007).        
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Adalimumab 
Adalimumab is a fully humanized  monoclonal  anti-TNF antibody, which is  admi- 
-nistered  either weekly or every other week  as a single s.c. injection. Preliminary 
experience has  shown  that adalimumab  has  been  effective  in  many  children 
who had not responded adequately to etanercept (Lovell et al. , 2004).                 
                                                                                                                                                          
Rituximab  
Rituximab   is  a chimeric  anti-CD20   monoclonal  antibody,  which    has   been 
approved  for  treatment  of  adult  onset  rheumatoid arthritis (Lachman, 2007).   
                                                                                                                      
Anakinra                                                                        
As the  first  line  therapy  for  systemic  JIA was associated with rapid solution of 
systemic symptoms and  prevention of refractory arthritis,  it shows  superiority in 
short term placebo controlled study ( Quartier  et al., 2011).                                   
                                                                                     
Humanized anti-interleukin 6 receptor antibody            
There is evidence  that  systemic  onset  JIA is in  part  an IL-6 mediated  disease 
, and  the use of humanized  anti-interleukin 6 such  as  tocilizumab  had  signific- 
ant  improvement  in  the  ACR improvement criteria and  disease activity indices 
,  an addition  to  decrease  in  acute-phase  reactant.  It is effective  in  treatment 
 of systemic –onset JIA and   may  be  useful  in patients with intractable disease 
 (Yokota  et al., 2008).                                                                                              
                                            
Autologus  Stem Cell  Transplantation                             
Autologus Stem cell transplantation has been considered in recalcitrant   cases    
of SoJIA, and  because  the  procedure  carries a significant  mortality  risk    
(usually from  macrophage  activation syndrome). Stem transplantation should be 
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 performed only in experienced centers after all other treatment options have 
failed (Weiss  and Ilowite , 2007).                                                                             
                                                    
2.2.6  Treatment of complications 
The treatment of JIA should be directed towards not only the inflammation of JIA 
but also for specific complications of JIA flexion contractures, weakness and 
difficulty with ambulation are not rare. The children with later complications 
should be referred for physical therapy. In rare cases joint replacement is 
indicated. In patients with temporomandibular joint involvement especially with 
significant micrognathia, surgical correction may be required, but this operation 
should  not be done until the facial bones are fully developed.                                 
Uveitis is initially treated with topical corticosteroids, if there is no improvement 
systemic corticosteroids and/ or MTX may be helpful, and in especially severe  
disease cyclosporine, adalimumab or infliximab have been used successfully.     
Osteoporosis  and  growth  retardation  are  associated  with  severe  polyarthritis 
subtypes of JIA.  Preliminary  studies  of  growth  hormone  therapy  have  shown 
some improvement in bone   mineral  contents   and  accelerated   linear   growth 
(Bechtold   et al., 2004;  Rooney  et al., 2000;  Simon et al.,  2003).  However, the 
use  of growth  hormone  therapy  also  has  been  associated   with  an  increase 
incidence of deformities, such as scoliosis (Lachman, 2007).                                 
                                                          
2.3  Methotrexate  
Methotrexate which formerly known as a methopterin, is an immunomodulator,  
by acting as antimetabolite and  antifolate drug. It is used  for in treatment of   
cancer,  autoimmune  disease,  ectopic pregnancy, and for  induction of medical 
abortion.                                                                                                                    
The beginning of use  of  MTX was in 1950 for treatment of leukemia.  MTX when 
used  at dose  of  10-15 mg/ m2  body surface  area (BSA)  per  week  acts  as an 
anti- inflammatory  agent  rather  than as  a cytotoxic  drug.  MTX  has  been   the 
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standard therapy for  children with  JIA especially   with polyarticular course,  and 
considered   as  the  drug  of  choice  in   the second  line  treatment  for  patients 
with JIA  who  did  not  respond   to  NSAIDs  (Ruperto  et al., 2004; Ravelli   and 
 Martini, 2000; Wallace, 1998).                                                                                
                
The short  and  long term data  suggest  that  MTX  is  a safe  drug  in  the 
pediatric population with rheumatic disease. And not  surprisingly  MTX is the   
DMARD of choice  in  JIA  either  as   monotherapeutic  drug   or  in combination 
with biologic agents (Gutierrez-Suarez  and Burgos-Vargas, 2010).                        
Usually, the starting dose of MTX in children with JIA is 10-15 mg/m2                       
and is administered weekly, either orally or parenterally (subcutaneously or 
intramuscular),  at  these  standard  doses,  the  oral  route  is  preferred  by most 
pediatric   rheumatologists  because  of   it 's  easer  administration  and   greater 
child  comfort,  furthermore   there  does  not   appear  to  be  any advantages 
related to efficacy or safety with either the oral or parenteral method of 
administration (Klein  et al., 2012).                                                                            
Some food  such as  milk-rich food may decrease MTX absorption, so it is better 
when drug is given without food.  Although MTX is effective for many patients, it 
does not work quickly, usually taking four to eight weeks before demonstrating 
it's benefits. Some physicians will initiate therapy with a low dose (0.2-0.35 mg/kg 
per day) of prednisone, to be taken until MTX has begun to take effect. The 
maximum therapeutic effect usually becomes apparent 4 to 6 months after the 
beginning of treatment and sometimes even after 12 months.  A higher dose up 
to 25-30 mg/m2/week may be considered in children who had only a partial 
response to the drug or have a more severe disease. Doses greater than          
15-20 mg/m2 are administered parenterally because of the decreased oral 
bioavailability of the drug at higher dose (Ravelli and Martini, 2000).                      
                                                                                                  
Interactions and Contraindications          
Salicylates may delay MTX 's clearance. Sulfonamides, salicylates, phenytoin 
displace  MTX from protein binding sites. Live virus  vaccines may result in           
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vaccine infection. Pyrimethamine, fluorouracil, NSAIDs increase toxicity of MTX 
by elevating serum MTX concentration ( do not use NSAIDs with high dose MTX 
therapy), penicillins may decrease renal clearance of MTX, probencide decrease 
the renal elimination of MTX. Also MTX may decrease theophylline clearance.     
                                                                                        
Contraindication for MTX use 
Hypersensitivity  to MTX, severe  renal  or hepatic impairment, lung fibrosis  and 
pre-existing profound bone marrow suppression. 
 
2.4  Health assessment in patients with JIA  
Assessment for children with JIA should be regularly done. The historical focus in 
assessment of children has  been on hard outcomes such as persistent disease 
activity, disease remission, joint damage, and organ system  damage.  A number 
of the measures of these outcomes   have   been grouped as a core set and used 
to define improvement (Giannini et al., 1997). Juvenile  idiopathic arthritis like  
most other chronic diseases  of childhood,  influences  all  aspects of  the  child ‘s 
life, including  physical, social, emotional,  intellectual and economic aspects, and 
affects the entire family with ultimate effects on the child’s overall outcome 
(Allaire  et al., 1992; Miller, 1993).                                                                            
                   
2.4.1  Instrument used to assess juvenile idiopathic arthritis 
 A- Measures of physical function   
-Childhood Arthritis Impact Measurement Scales (CHAIMS)  
-Juvenile Arthritis Assessment Scale (JAFAS) and Report (JAFAR) 
-Childhood Health  Assessment Questionnaire (CHAQ) 
-Juvenile Arthritis Self-Report Index (JASI) 
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B- Measures of quality of life 
 
Disease specific 
-Juvenile Arthritis Quality of life Questionnaire (JAQQ)            
-Childhood Arthritis Health Profile (CHAP) 
Generic 
 -Childhood Health Questionnaire (CHQ) 
-Pediatric  Quality of Life Inventory Scales (Peds QL) 
-Quality of My Life Questionnaire (QOMLQ)          
                                 
2.4.2  CHAQ 
CHAQ is a disease- specific measure of functional status that comprises two 
indices focus on physical function. The disability index assesses function in eight 
areas that include dressing, grooming, eating and general physical activities 
distributed among a total of 30 items. Each question is rated on difficulty in 
performance and is scored from 0 to 3. The disability index is calculated as the 
mean of eight functional areas. Discomfort is determined by the presence of pain 
measured by a 100-mm visual analogue scale. The CHAQ has been shown to be 
a useful instrument for evaluating outcome in longitudinal studies (Minden  et al., 
2000; Oen, et al, 2003), it has been shown to have reasonable responsiveness in 
clinical drug trials (Lovell et al., 2000) and in the evaluation of rehabilitative 
interventions (Fan et al., 1998).                                                                                
The CHAQ has  excellent  reliability and validity, and  responsiveness, it also has 
good  discriminative  properties and  can be administered  to children  of  all ages 
and in several  languages, and because it is short and easy to use, it is used with 
increasing frequency in the clinical settings (Duffy CM, 2007).        
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2.5  Definition of improvement and remission 
2.5.1  Measurement of response in JIA 
Until the mid-1990’s, the assessment of clinical response in JIA was not 
standardized, there had been no single uniform definition of improvement for use  
in the clinical trials of JIA and multiple outcome measures were utilized and 
various trials used different endpoints.                                                                      
Previous response criteria focused on single outcome measures, including the 
percentage improvement in number of active joints, physician preference, and 
overall improvement in physician global assessment, which led to difficulty in 
comparing study outcomes.                                                                                      
In 1997 the pediatric core set and the American college of Rheumatology (ACR)  
Pediatric 30 response criteria has been developed. The ACR Pediatric 30 was 
initially designed to distinguish between active treatment and placebo, it is well 
studied and validated but more commonly used in research versus practice.          
ACR Pediatric 30 is now used as the primary outcome measure for trials of 
biologic agents and second line therapies and remains the only prospective 
validated measure of disease activity in JIA (Ringold and Wallace, 2007).              
The components of ACR Pediatric criteria include the following: 
-Physician‘s global assessment of overall disease activity (measured on a 10-cm 
visual analogue scale {VAS}).          .                                                               
-Parents (or, if appropriate in age, patient) global assessment of overall well-
being measured on a 10-cm VAS.                                                                            
-Functional ability (usually assessed with the CHAQ). 
-Number of joints with active arthritis.  
-Number of joints with limited range of motion.  
-Erythrocyte Sedimentation Rate ( ESR ).  
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ACR Pediatric 30 means a minimum of 30 % improvement from baseline in a 
minimum of 3 out the above 6 components with no more than one component  
worsening  more  than  30 %.   Also  PedACR  50%  and  PedACR  70%  defined 
as  50 and 70  percent  improvement   in  a minimum  of  3  out the  above  6  
components  with no more than one component worsening more   than 30 %.      
                                                                                                    
2.5.2  Definition of remission 
The primary goal in management of JIA is the achievement and maintenance 
remission. Until recently , reaching remission  has been difficult to achieve in 
most  forms   of  JIA,  but with  the  development  of new therapeutic agents and 
combination treatment strategies, more children with arthritis can experience 
protracted  periods  of  low  levels  of  disease  activity  and  in limited  number of 
cases, a complete clinical remission, but it is difficult to define precisely with a 
single  disease  activity  measure,  although  many  definitions  for  remission 
hasbeen developed, until recently no uniform and widely accepted criteria for 
defining remission in JIA.                                                                                          
According  to  the  preliminary  criteria of clinical  remission the patients divided in 
three groups:-  patients with inactive disease, clinical  remission  with  medication 
and clinical remission without medication (Table 2).          
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Inactive disease 
 
1. No joints with active arthritis* 
2. No fever, rash, serositis, splenomegaly, or generalized lymphoadenopathy   
attributable to JIA 
3. No active uveitis (to be defined) 
4. Normal ESR or CRP (if both are tested, both must be normal) 
5. Physician’s global assessment of disease activity indicates no disease activity 
(i.e., best score attainable on the scale used) 
 
Clinical remission 
Two types of clinical remission are proposed: 
 
1. Clinical remission with medication. The criteria for inactive disease must be 
met for a minimum of 6 consecutive months while the patient is taking 
medication. 
 
2. Clinical remission without medication. The criteria for inactive disease must be 
met for a minimum of 12 consecutive months while the patient is off all anti-
arthritis and anti-uveitis medication 
*As defined by the American College of Rheumatology: A joint with swelling 
not due to bony enlargement or, if no swelling is present, limitation of motion 
accompanied either by pain on motion and/or tenderness. Isolated finding of 
pain on motion, tenderness, or limitation of motion on joint examination may be 
present only if explained by either prior damage attributable to arthritis that is 
now considered inactive, or non rheumatologic reasons such as trauma 
(Ravelli and Martini, 2006) 
 
Table 2: Preliminary criteria for inactive disease and clinical remission of JIA 
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2.6   Objectives 
Methotrexate is the most common second line therapeutic agent used in 
treatment of JIA worldwide, however, there is  variation  in the  clinical response  
and toxicity observable  between the  patients  who  used  MTX. Although serious 
toxicity in patients using MTX is uncommon, a prevalence of adverse effects as 
high as 42 % has  been reported  (Ravelli  et al,  1998).                                          
The  main goal  of JIA treatment is the  achievement of  wellbeing   with   minimal 
risk  of  side effects. Identification of  predictors of  response is helpful  to develop 
recommendations  for  MTX use, especially  starting  of MTX  as  well  as  further 
continuation or early discontinuation and starting use of biological drugs.  
The aim of this study is to determine whether demographic, clinical, articular and 
laboratory variables  at  baseline  and  during   follow up  at  month  3, 6  and  12 
predict  MTX response in patients with juvenile idiopathic arthritis.                         
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3.  Patients and Methods 
3.1  Patient selection                                                 
Patient's  data were taken from the German BIKER Registry founded in 2001. 
The registry is a non-interventional long term study and has been approved by 
the ethics committee of the Aerztekammer Nordrhein, Duesseldorf, Germany. 
Since 2005 patients newly started with methotrexate were included into the 
registry. Data of patients admitted to the registry until December 31, 2010  were 
used for this analysis.                                                           
The inclusion criteria  used were : 
1-Diagnosis of  JIA according to the modified ILAR criteria (Edmonton 2001), all 
categories. 
2- Treatment with MTX just started. 
3- Pretreatment data set available 
4- Duration of MTX treatment of at least 3 months.  
Patients who currently receive or have been received biologics (Etanercept, 
Adalimumab, Infliximab, Tocilizumab……) were excluded. 
Until 31.12.2010 the total number of patients included in the registry was 1063. 
The total number of patients fulfilling all inclusion and exclusion criteria was 915 
patients  who belong to all categories of JIA. 
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Reasons of non selection Number of patients 
Pretretment with biologics 27 patients 
Wrong diagnosis (Sharp syndrom, 
uveitis without JIA or vasculitis) 
4 patients  
Treatment duration < 3 months 18 patients 
Pretreatment data set incomplete 99 patients 
 
Table 3:  Reason for exclusion of patients registered before 31.12.2010 
3.2  Evaluation of response to treatment 
In this study the response to treatment  was analysed at 3 months, 6 months, and 
at 12  months.  At  each  time  the  patients  were  divided   into  responders  and       
non-responders according the American Collage of Rheumatology Paediatric 
(PedACR) 30 or 70 improvement criteria, this means 30% or 70% improvement 
from baseline  in at least three of the following six variables: 
-Physician's global assessment of overall disease activity.  
-Parent's (or patient) global assessment of well-being. 
-Number of joints with active arthritis. 
-Number of joints with limited range  of motion. 
-Childhood Health Assessment Questionnaire (CHAQ) 
-Erythrocyte sedimentation rate (ESR) 
As well as there is no more than one of the remaining variables worsened by 
more than 30 %. 
The predefined parameters with a potential influence on response which included 
in the study listed in table 4. 
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Demographic parameters Gender, age at onset of disease, age 
at start of treatment with MTX, disease 
duration until start of treatment.  
Clinical parameters JIA category, previous 
unresponsiveness to other DMARD, 
global disease activity, pain 
assessment and child disability 
assessed by CHAQ. 
Articular parameters No. of active joints, No. of joints with 
LOM No. of tender joints and morning 
stiffness. 
Laboratory parameters 
 
ESR, CRP, RF, ANA and HLA B27 
 
Table 4: Parameters of interest with a potential influence on response 
                                                              
3.3  Statistics 
Populations for analysis in our study are patients with a treatment duration for at 
least 3 months. The time of analysis of response was 3 months, 6 months, 12 
months, at these times the patients divided in the following groups : 
Group 1a (PedACR30 non-Responders) at month 3 
Group 1b (PedACR30 non-Responders) at month 6 
Group 1c (PedACR30 non-Responders) at month 12 
Group 2a (PedACR30 Responders) at month 3 
Group 2b (PedACR30 Responders) at month 6 
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Group 2c (PedACR30  Responders) at month 12 
Group 3a (PedACR70 non-Responders) at month 3 
Group 3b (PedACR70 non-Responders) at month 6 
Group 3c (PedACR70 non-Responders) at month 12 
Group 4a (PedACR70 Responders) at month 3 
Group 4b (PedACR70 Responders) at month 6 
Group 4c (PedACR70 Responders) at month 12 
Parameters are described as medians with first and third quartiles or mean ± 
standard deviation (SD) for quantitative variables and as absolute frequencies 
and percentages for qualitative variables. To detect  relations  between  Ped- 
ACR response and the potentially influencing parameters, Pearson or Spea- 
rman correlation coefficients were calculated, depending on parameter types. 
Multivariate logistic regression analyses  were performed to evaluate the  role  of 
all factors that were significantly correlated with the response parameters 
(PedACR 30 or 70 response at months 3, 6, or 12).  For the final model of each 
response parameter the adjusted odds ratios (OR) with confidence interval for 
the significant factors and the area under the receiver operating curve (AUC) 
were calculated. Analysis was performed using IBM® SPSS® Statistics version 
21. The level of significance was set at 5%. 
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4.  Results 
4.1  Characters of the study sample 
4.1.1  Gender  of the patients 
The patient population consisted of 915 Patients in whom the diagnosis of 
juvenile idiopathic arthritis has been given according to the ILAR criteria. In our 
study the females represent 68.5 % of the sample (627 patients), while the males 
represent  31.5 % of the sample (288 patients). 
 
 
Figure 1: Distribution of patients according to gender 
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4.1.2  JIA categories 
As seen in figures No. 2, 3 and table No. 5, persistent oligoarthritis is the most 
common JIA category in our study sample, 271 patients (29.6 %)  have this 
subtype, 247 patients (26.9 %) had RF negative polyarthritis and only 23 patients 
(2.5 %) had unclassified arthritis. 
JIA category No. of patients Gender Age at start of 
treatment with  
MTX  years 
(Mean+/-SD) 
male female 
Systemic onset JIA  26 (2.8 %) 14 (53.8 %) 12 (46.2 %) 6.9 +/-4.66 
 
Seronegative 
polyarthritis  
247 (26.9 %) 50 (20.2 %) 197 (79.8 %) 9.4 +/-4.64 
Seropositive 
polyarthritis  
29 (3.2 %) 3 (10.4 %) 26 (89.6 %) 12.4 +/-4.65 
Persistent 
oligoarthritis  
271 (29.6 %) 90 (33.2 %) 181 (66.8 %) 8.3 +/-4.65 
Extended  
oligoarthritis 
118 (12.9 %) 37 (31.4 %) 81 (68.6 %) 8.6 +/-4.5 
Enthesitis-related 
arthritis 
120 (13.2 %) 66 (55 %) 54 (45 %) 12.9 +/-4.65 
Psoriatic arthritis     
 
81 (8.8 %) 21 (25.9 %) 60 (74.1 %) 10.4 +/-4.65 
Unclassified JIA     
     
23 (2.5 %) 7 (30.4 %) 16 (69.6 %) 9.1 +/-4.66 
 
Table 5:  Distribution of patients according to categories of JIA, gender and age at start 
of treatment with MTX 
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Figure 2:  Mean age at start of MTX in each JIA category  
 
 
Figure 3:  Distribution of patients according to the gender and JIA categories 
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4.1.3  Age at onset of the disease 
The mean age (+/- SD) at onset of the disease was 7.4+/-4.4 years. The median 
age was 6.9 years, the range (0,3–15.9) years. Patients below the age of 4 
contributed to the largest group with  267 (29.1 %) of all patients.  The detailed 
data are given in table No. 6 . 
 
Table  6:  Distribution of patients according to the age at onset of disease  
 
4.1.4  Age at start of treatment  with methotrexate 
The mean age (+/-SD)  at which the treatment with  methotrexate has been 
started was  9.5+/-4.7 years. The median age was 9.9 years (range 1.1-18.1 
years). 
 
Table 7:  Distribution of patients according to the age at onset of treatment. 
                       
 
 
                                  
 
Age group Number Percent 
 < 4 years 267 29.1 % 
 4-8 years 239 26.1 % 
 8-12 years 222 24.3 % 
 12-16 years 187 20.4 % 
Percent  Number Age group 
15.3 %  140 < 4 years   
25.4 % 232 4-8 years 
22.1 % 202 8-12 years  
37.3 % 341 12-16 years 
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4.1.5  Disease duration until start of treatment with MTX  
The mean  disease  duration until  start of  treatment  with MTX was (+/-SD)  2.2  
+/-2.7, while  the  median was  0.99  year (range 0.02-16.3)  years. The disease 
duration in about 50.3 % of  patients (460 patients) was less than 1 year ( Table 
No. 8).                                                                                 
 
Table  8:  Distribution of patients according to disease  duration before start of treatment 
with methotrexate                 
 
4.1.6  Medical treatment before  start of  MTX                                            
About  91.1 % of  patients  have  been  treated with  NSAIDs (834 patients),  and 
21.2 % of patients were treated with oral corticosteroids (194 patients) in addition 
to 34.6%  of patients  (317 patients)  have  been  treated with intraarticular cortic- 
osteroids, 87 (9.5 %) patients  have received other DMARD  before starting  MTX 
(Tables No 9 and 10).                                                                                                   
                     
        
 
 
Table 9:  Medical treatment before starting MTX      
 
                                         
 
 
 
                                      
Percent               Number         Disease duration 
50.3 %  460         <1 year                               
  49.7 %                                    455  >1 year               
Type of drug  No. of patients    percent 
NSAID         834       91.2 % 
Oral corticosteroids         194       21.2 % 
Intra-articular corticosteroids         317       34.6 % 
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Table 10:  Distribution of DMARDs used before starting MTX  
 
4.1.7  Articular characters of the patients 
As outlined in table No. 11 the mean of  No. of active joints at baseline was 5.9+/-
7.5 and the median was 3, the mean of swollen joints was 4.9+/-6.8 and the 
median 3,  the mean of tender joints 5.8+/-7.2 and the median 3, while the mean 
of joints with limitation of movement was 5.7+/-7.5 and the median was 3. 542 
(59.2 %) patients had morning stiffness, the mean duration of morning stiffness 
was 55.7+/-72.2 minutes and the median was 30 minutes.  
 
Table 11:  Articular characters of the patients 
 
 
 
 
 
Type of DMARD No. of patients 
Azathioprine           6 
(Hydroxy)chloroquine          38 
Cyclosporine A           5 
Leflunomide           3 
Sulfasalazin          34 
Immunoglobulins           1 
 Active joints Swollen 
joints 
Tender 
joints 
LOM joints Duration of  
MS (min.) 
Mean 5.89 4.92 5.58 5.72 55.67 
Median 3 3 3 3 30 
SD 7.53 6.8 7.23  7.47 72.15 
Minimum 0.00 0.00 0.00 0.00 1 
Maximum 56 54 54 58 720 
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4.2   Minimal  Response (PedACR30) 
4.2.1  PedACR30 at month 3 
 
 At month 3, 566 (77.4 %) patients were responders according to the PedACR 30 
criteria, 165 (22.5 %) were non responders. Among 165 patients who were non 
responders, 116 patients were females (70.3 %). Their median age (first to third 
quartile) at onset of disease was 6.4 (3.8-10.5) years, the median age at start of  
MTX was 9.5 (6-13.3) years, and the median of disease duration was 1.1 (0.4-
3.2) years, 54.5 % of non responders (90 patients) had disease duration more 
than 1 year. The most common  JIA category was persistent oligoarthritis in 48 
(23.2 %), followed by polyarticular RF negative JIA in 38  (19 %) patients. ANA 
were detected in 76 (48.4 %) patients, while HLA B27 were positive in 35 (22.9 
%) patients. 28 (16.9 %) patients used steroids and 149 (90.3 %) used NSAIDs. 
At month 3 the PedACR30 non-responder patients had  a median of 2 active 
joints (1-3), and a median of 2 (1-4) joints with limitation of movement, 1 (0-3)  
with swollen joints as well as median of 2 (1-4) with tender joints, 68 patients 
(41.2 %) had morning stiffness with median of 30 joints (15-60), a physician’s 
global assessment of overall  disease activity of 29 (19-51.7), ESR of  12 mm/ 
h(6-23.5), CRP of 3 (1-7) mg/ dl, a parents evaluation of child's overall wellbeing 
of 27 (8-46) and a CHAQ of 0.25 (0.0-0.6) (Tables 12,13, 14 and 15). 
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 Figure 4:  PedACR 30 at 3 months in different JIA categories 
 
4.2.2  PedACR30 at month 6 
 
At month 6, 528 (81.3 %) patients were responders, 121 (18.6 %) patients were 
non responders. Among 121 patients who were non responders, 85 (70.2 %) 
patients were females, their median age (first to third quartile) at onset of disease  
was 9.1 (4.2-12) years, median age at start of MTX was 12.2 ((7.8-12.4) years 
and the disease duration 1.8 (0.7-3.9) years, 72 % of non responders (87 
patients) had disease duration more than 1 year. According to JIA categories 
19.1 % of non-responders were persistent oligoarthritis category (36 patients), 
enthesitis related arthritis in 27 (31.4 %) and polyarticular RF negative in 23 (13.7 
%) patients.  ANA were detected in 47 (39.8 %) patients, HLA B27 were positive  
in 26 (23 %) patients, 27 (22.3 %) patients used steroids and 107 (88.4 %)  
patients used NSAIDs. The median of  active joints  was  2 (0-4),  of  joints  with  
limitation of movement was 2 (1-4), of swollen joints was 1 (0-3), of tender  joints  
was 2 (0-6), number of patients with morning stiffness was 56 (46.3 %) and 
median of duration of morning stiffness  was 30 minutes (10-60), a physician’s 
evaluation of  disease  activity  was 25 (17-36.5), ESR was 10 mm/h (6-19), CRP 
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 was 3 (1-6.6) mg/ dl, a parent evaluation of child's overall well-being was 27.5 
(10-55) and a CHAQ was 0.25 (0-0.75) (Tables 12,13, 14 and 15). 
 
 
 
 
Figure 5:  PedACR 30 at 6 months in different JIA categories 
 
 
4.2.3  PedACR30 at month 12 
 
 
At month 12, 587 (83.1 %) patients were responders, 120 (16.9 %) patients were 
non responders. Among 120 patients who were non responders, 82 patients are 
females (68.3 %). Their median age (first to third quartile) at onset of disease 
was 9 (4.5-12.5) years, the median age at start of  MTX was 12.3  (7.8-14.7)  and  
disease  duration 1.3 (0.5-3.4) years, 63 %  of  non responders (76 patients)  had  
disease duration more than 1 year. The JIA category was persistent oligoarhritis 
in 36  patients (16.7 %), polyarticular  RF  negative  in  26  patients (13.5 %)  and  
enthesitis related arthritis in 19 patients (22.6 %). ANA were detected in 51 
(42.9%) patients, while HLA B27 were positive in 25 (22.7%) patients. At month 
12 the PedACR30 non-responder patients had  a median of 2 active joints (0-4), 
and also a median of 2 (0.75-4) joints with limitation of movement, of swollen 
joints was 1 (0-4), of  tender joints  was 2 (0-5), number of patients with  morning  
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stiffness was 54 ( 45%) and median of duration of morning stiffness  was 1 (1-2), 
a physician’s evaluation of disease activity of 31 (20-55), ESR of  10 mm/ h (5-
21), CRP of 2.9 (1-7) mg/ dl, a parent evaluation of child's overall well-being of 30 
(9-54.5) and a CHAQ of 0.12 (0-0.6) (Tables 12, 13, 14 and 15).   
 
 
 
Figure 6: PedACR 30 at 12 months in different JIA categories 
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Figure 7: PedACR30 in different JIA categories at month 3, 6 and 12 
 
 
 
 
 
Table 12: Laboratory characteristics at start of treatment  in PedACR30  responders and 
PedACR30 non-responders. Data are in numbers (%) or median (first to third quartile) 
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JIA Categories
ACR 30 Month 3 to 12 3
6
12
Character PedACR 30 At 3 months 
No. of patient  731 
PedACR 30 At 6 months  
No. of patient   649  
PedACR 30 At 12 months 
No. of patient  707 
 Responder 
566 
 
Non 
responder 
165  
Responder 
528 
 
Non 
responder 
121 
Responder 
587 
 
Non 
responder 
120 
ANA 
positive 
271     
(49.2 %) 
 
76          
(48.4 %) 
265     
(52.1 %) 
47         
(39.8 %) 
306          
(54 %) 
51         
(42.9 %) 
ANA 
negative 
280     
(50.8 %) 
 
81          
(51.6 %) 
244     
(47.9 %) 
71         
(60.2 %) 
261         
(46 %) 
68          
(57.1 %) 
HLA B27 
positive 
94  
(19.2 %) 
 
35          
(22.9 %) 
84       
(18.5 %) 
26            
(23 %) 
 94      
(18.5 %) 
25         
(22.7 %) 
HLA B27 
negative 
395     
(80.8 %) 
 
118       
(77.1 %) 
370     
(81.5 %) 
87            
(77 %) 
415     
(81.5 %) 
85          
(77.3 %) 
ESR  
(mm/ h) 
18          
(10.0-31) 
 
12            
(6.0-23.5)  
17             
(10-31.7) 
10             
(6-19) 
18             
(10-33) 
10             
(5-21)  
CRP  
(mg / dl) 
4.2            
(1.1-12) 
3                  
(1-7) 
4.5             
(1.5-13) 
3                
(1-6.6) 
4.9             
(1.5-14) 
2.9             
(1-7) 
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Table 13: Demographic and clinical characteristics at start of treatment in PedACR30  
responders and PedACR30 non-responders. Data are numbers (%) or median (first to third 
quartile) 
 
 
 
 
 
 
Character 
 
PedACR 30 At 3 months 
No of patient  731 
 
PedACR 30 At 6 months  
No of patient  649   
 
PedACR 30 At 12 months 
No. of patient  707 
  
Responder 
566 
(77.4 %) 
 
Non 
responder 
165 (22.6 %) 
 
Responder 
528 
(81.4 %) 
 
Non 
responder 
121 (18.6 %) 
 
Responder 
587 
(83.1 %) 
 
Non 
responder 
120 (16.9 %) 
 
Female 
 
386(68.2 %) 
 
 
116 (70.3 %) 
 
365 (69.1 %) 
 
85 (70.2 %) 
 
408 (69.5%) 
 
82 (68.3%) 
 
Male 
 
180 (31.8  %) 
 
49 (29.6  %) 
 
163 (30.8  %) 
 
36 (29.7 %) 
 
179 (30.5%) 
 
38(31.6%) 
 
Concomitant use 
of NSAID 
 
 
514 
 (90.8  %) 
 
 
149  
(90.3  %) 
 
483  
(91.5  %) 
 
107  
(88.4  %) 
 
546   
(93 %) 
 
105 
 (87.5%) 
 
Concomitant use 
of Corticosteroid 
 
125    
(22.1 %) 
 
 
28        
(16.9 %) 
 
 
113   
(21.4 %) 
 
 
27      
 (22.3 %) 
 
 
127   
(21.6 %) 
 
23       
(19.2 %) 
  
Age at onset of 
disease 
 
 
 
6.8      
(3.3-11) 
 
6.4           
(3.8-10.5) 
 
6.1           
(2.9-10.9) 
 
9.1           
(4.2-12) 
 
6.3           
(3-10.9) 
 
9              
(4.5-12.5) 
 
Age at MTX start 
 
9.7   
(5.3-13.5) 
 
9.5              
(6-13.3) 
 
9.3           
(5.2-13.2) 
 
12.2         
(7.8-12.4) 
 
 
9               
(4.9-13.2) 
 
12.3         
(7.8-14.7) 
 
Disease duration 
before MTX start 
 
0.9           
(0.3-2.9) 
 
1.1          
(0.4-3.2) 
 
0.8         
 (0.3-3) 
 
 
1.8           
(0.7-3.9) 
 
0.7           
(0.3-2.7) 
 
1.3          
 (0.5-3.4) 
 
Physician global 
assessment of   
disease activity 
 
40          
(25-65) 
 
29             
(19-51.7) 
 
38             
(24-60) 
 
25              
(17-36) 
 
43.5          
(25-66) 
 
31             
(20-55) 
Parents 
evaluation of 
overall well- 
being 
 
44             
(19-61) 
 
27               
(8-46) 
 
40             
(18-60) 
 
27.5          
(10-55) 
 
41              
(18-59) 
 
30                
(9-54.5) 
Parents 
evaluation of  
child´s pain 
 
40             
(15-60.2) 
 
26.5         
(4.2-53) 
 
37             
(15-58) 
 
32                
(8-59) 
 
38              
(15-57) 
 
32             
(4.5-59.5) 
 
CHAQ 
 
0.5 
(0.12-0.87) 
 
0.25            
(0-0.6) 
 
0.37        
(0.12-0.8) 
 
0.25            
(0-0.75) 
 
0.5          
(0.12-0.8) 
 
 
0.12            
(0-0.6) 
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Table 14: Articular characteristics at start of treatment  in PedACR30  responders and 
ACR30 non-responders. Data  are in median (first to third quartile) 
 
 
 
 
 
 
Table 15: Distribution  of  patients  according  to JIA  categories divided into  PedACR30    
responders and non-responders at month 3, 6 and 12 
 
 
 
 
 
 
 
Character PedACR 30 At 3 months 
No of patient  731 
PedACR 30 At 6 months  
No of patient   649  
PedACR 30 At 12 months 
No. of patient  707 
 Responder 
566 
  
Non responder 
165 
Responder 
528 
 
Non 
responder 
121 
Responder 
587 
 
Non 
responder 
120 
No. of active 
joints 
 4 (2-8)  2 (1-3)      4 (2-7.25) 2 (0-4) 4 (2-8) 2 (0-4) 
No of tender 
joints  
3 (2-7) 2 (1-4) 3 (2-7) 2 (0-6) 3 (2-7) 2 (0-5) 
No. of 
swollen 
joints 
3 (2-7) 1 ( 0-3) 3 (1.75-6) 1 (0-3) 3 (1-6) 1 (0-4) 
No. of joints 
with  LOM 
4 (2-8) 2 (1-4) 4 (2-7) 2 (1-4) 4 (2-7.5) 2 (0.75-4) 
Duration of 
MS 
 
30 (20-60) 30 (15-60) 30 (20-60) 30 (10-60) 30 (16-60) 42.5 (30-60) 
JIA categories PedACR 30 at 3 months 
 
PedACR 30 at 6 months PedACR 30 at 12 months 
 Responder 
566 
(77.4 %) 
Non 
responder 
165(22.6 %) 
Responder 
528 
(81.4 %) 
Non 
responder 
121(18.6 %) 
Responder 
587 
(83.1 %) 
Non 
responder 
120(16.9 %) 
Systemic 
onset JIA 
21   
(84%) 
 
4       
(16%) 
18      
(90%) 
2          
(10 %) 
14   
(82.4 %) 
3     
(17.6 %) 
Seronegative       
Polyarthitis            
162       
(81 %) 
38         
 (19%) 
145 
 (86.3%) 
23 
(13.7 %) 
166  
(86.5 %) 
26 
 (13.5 %) 
 Seropositive 
Polyarthritis 
18  
(81.8 %) 
 
4    
(18.2%) 
20  
(90.9%) 
2          
(9.1 %) 
20    
(86.9 %) 
3   
(13.1 %) 
 Persistent  
Oligoarthitis 
159 
(76.8 %) 
 
48  
(23.2%) 
153  
(80.9%) 
36  
(19.1 %) 
179 
(83.3 %) 
36 
(16.7 %) 
 Extended  
Oligoarthritis 
71  
(73.9%) 
 
25  
(26.1%) 
74  
(87.1%) 
11     
(12.9 %) 
81    
(85.3 %) 
14     
(14.7 %) 
 ERA 66  
(72.5 %) 
 
25  
(27.5 %) 
59     
(68.6 %) 
27  
 (31.4 %) 
65  
(77.4 %) 
19 
(22.6 %) 
 JPsA 55   
(76.4 %) 
 
17 
(23.6 %) 
50    
(72.5 %) 
19  
(27.5 %) 
50   
(74.6 %) 
17 
(25.4 %) 
unclassified 
JIA 
14            
(77.8 %) 
 
4             
(22.2 %) 
9                  
(90 %) 
1                
(10 %) 
 
12    
(85.7 %) 
2             
(14.3 %) 
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4.3  Strong Response (PedACR70-Response) 
4.3.1  PedACR70 at month 3 
The table No.17 shows that 416 (56.9 %) patients are PedACR70 non responder 
at month 3, among them there are 297(71.4 %) patients, who were females. 
Their median age (first to third quartile) at onset of disease was 6.6 (3.6-11.1) 
years, age at start of  MTX was 9.7 (5.9-13.8) and disease duration 1 (0.4-3.2) 
years, 53 % of non responders (221 patients) had disease duration more than 1 
year. The JIA category was persistent oligoarhritis in 123 (59.4 %), RF negative 
polyarthritis in 118 (59 %) and enthesitis related arthritis in 56 (61.5 %) patients 
(Table 19). ANA were detected in 200 (49.7%) patients, while HLA B27 were 
positive in 76 (20.5 %) patients. 75 (18 %) patients used corticosteroids and 380 
(91.3 %) used NSAIDs. At month 3 the PedACR70 non-responder patients had  a 
median of 3 active joints (1-5), and also a median of 3 (1-5) joints with limitation 
of movement, number of patients with morning stiffness was 232 (55.8 %) and 
median of duration was 30 (15-60) minutes,  a physician’s evaluation of disease 
activity of 33 (22-55), ESR of  15 mm/ h (8-25), CRP of 4 (1-9.2) mg/dl, a parent 
evaluation of child's overall well-being of 35 (15-55) and a CHAQ of 0.3 (0-0.7) 
(Tables 16,17, and 18). 
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  Figure  8: PedACR 70 at 3 months in different JIA categories. 
 
4.3.2   PedACR70 at month 6 
 
 
The table No. 17 shows that 281 (43.3 %) patients are PedACR70 non responder 
at month 6, among them there are 199 (70.8 %) patients, who were females. 
Their median age (first to third quartile) at onset of disease was 6.7 (3.8-11.3) 
years, age at start of  MTX was 10.4 (6.3-14) and disease duration 1.4 (0.5-3.3) 
years, 63 % of non- responders (177 patients) had disease duration more than 1 
year. The JIA categories were persistent oligoarhritis in 76 (40.2 %), RF negative 
polyarthritis in 65 (38.7 %) and enthesitis related arthritis  in 47 (54.7 %) patients 
(Table 19). ANA were detected in 127 (46.3 %) patients, while HLA B27          
were positive in 51 (19.8 %) patients. 58 (20.6 %)  patients  used   corticosteroids  
And  254 (90.4 %)  used   NSAIDs.  At  month 6  the  PedACR70  non- responder  
patients had  a median of 3 active joints (1-5), and also a median of  3 (1-5) joints  
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with limitation of movement, the number of  patients with  morning  stiffness  was 
155 (55.2 %) and the median duration was 30 (10-60) minutes, while a 
physician’s evaluation of disease activity of 29 (20-52.7), ESR of 12 (7-24) mm/h, 
CRP of 3 (1-7) mg/dl, a parent evaluation of child's overall well-being of 31 (11-
58) and a CHAQ of 0.25 (0.0-0.8) (Tables 16,17, and 18). 
 
 
Figure  9:  PedACR 70 at 6 months in different JIA categories 
 
 
4.3.3 PedACR70 at month 12 
 
As seen in table No. 16 there are 241 (34.1 %) patients are PedACR70 non 
responder at month 12, among them there are 172 (71.4 %) patients, who were 
females. Their median age (first to third quartile) at onset of disease was 8.6  
(3.9-12.1) years, age at start of MTX was 11.4 (6.8-14.5) years, and  disease  
duration 1.3 (0.5-3.4) years, 60 % of  non responders (144 patients)  had disease  
duration more than 1 year. The JIA category was persistent oligoarhritis in 70 
(32.6 %), RF polyarthritis  negative  in  57 (29.7 %)  and  Psoriasis arthritis  in  33  
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(49.3 %) patients (Table 19). ANA were detected in 117 (48.9 %) patients, while 
HLA B27 were positive in 42 (18.8 %) patients. 43 (17.8 %) patients used 
corticosteroids and 221 (91.7 %) used NSAIDs. At month 12 the PedACR70 non- 
responder patients had  a median of 2 active joints (1-5), and also a median of 2 
(1-5) joints with  limitation  of  movement, the number of patients with morning 
stiffness was 120 (49.8 %) and the median duration was 30 (15-60) minutes, 
while a physician’s  evaluation of disease  activity  of 30 (20-55), ESR of  12 (6.5-
24) mm/h, CRP of 3 (1-7) mg/dl, a parent evaluation of child's overall well-being 
of 31.5 (10-57) and a CHAQ of 0.25 (0-0.75) (Tables 16,17, and 18). 
 
 
Figure  10:  PedACR 70 at 12 months in different JIA categories 
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Figure 11: PedACR70 in different JIA categories at month 3, 6 and 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16:  Laboratory characteristics at start of  treatment  in PedACR70  responders 
and ACR70 non-responders. Data are in numbers (%) or median (first to third quartile) 
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(%
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JIA Category
PedACR 70 
Month 3
Month 6
Month 12
Character PedACR 70 At 3 months 
No. of patient   731 
PedACR 70 At 6 months  
No. of patient   649  
PedACR 70 At 12 months 
No. of patient   707 
 Responder 
315 
(43.1 %) 
Non 
responder 
416 (56.9 %) 
 
Responder 
368 
(56.7 %) 
Non 
responder 
281(43.3 %) 
Responder 
466 
(65.9 %) 
Non 
responder 
241(34.1 %) 
ANA 
positive 
147 (48 %) 
 
 
200 (49.7 %) 
 
185  (52.4 %) 127(46.3 %) 240  (53.7%) 117(48.9 %) 
ANA 
negative 
159 (52 %) 
 
 
202 (50.3 %) 
 
168  (47.6 %) 147 (53.7%) 207  (46.3%) 122(51.1 %) 
HLA B27 
positive 
 53 (19.6%) 
 
 
76 (20.5 %) 59 (19 %) 51 (19.8 %)  77 (19.4 %) 42 (18.8 %) 
HLA B27 
negative 
218 (80.4 %) 
 
 
295 (79.5 %)   
 
251 (81%) 206(80.2 %) 319 (80.6 %) 181(81.2 %) 
ESR  
(mm/ h) 
18            
(9.0-35) 
15             
(8.0-25) 
19.5          
(10-36.5)          
 
12               
(7-24) 
19             
(10-36) 
12             
(6.5-24) 
CRP  
( mg/ dl) 
4.4             
(1.2-13.9) 
4                  
(1-9.2) 
 5                
(2-15) 
3                     
(1-7) 
5                  
(2-15.35) 
3                
(1-7) 
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Table 17: Demographic and clinical characteristics at start of treatment in PedACR70  
responders and PedACR70 non-responders. Data are in numbers (%) or median (first to 
third Quartile) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Character PedACR 70 At 3 months 
No. of patient   731 
PedACR 70 At 6 months  
No. of patient  649    
PedACR 70 At 12 months 
No. of patient   707 
 Responder 
315 
(43.1 %) 
Non 
responder 
416(56.9 %) 
Responder 
368 
(56.7 %) 
Non 
responder 
281(43.3 %) 
Responder 
466 
(65.9 %) 
Non 
responder 
241(34.1 %) 
 
Female 
205        
(65.1 %) 
 
297        
(71.4 %) 
251   
(68.2 %) 
199             
 (70.8 %) 
318  
(68.2 %) 
172  
(71.4 %) 
 
Male 
110    
(34.9 %) 
 
119  
(28.6 %) 
117  
(31.8 %) 
82       
(29.2 %) 
148  
(31.8 %) 
69       
(28.6 %) 
Concomitant 
use of NSAID  
283       
(89.8 %) 
380     
(91.3 %) 
336    
(91.3 %) 
254    
(90.4 %) 
430   
(92.3 %) 
221    
(91.7 %) 
 
Concomitant 
use of 
Corticosteroid  
78       
(24.7 %) 
 
75        
(18 %) 
 
82       
(22.3 %) 
 
58       
(20.6 %) 
 
107  
(22.9 %) 
43       
(17.8 %) 
 Age at onset of 
disease 
 
6.6            
(3.1-10.8) 
6.6           
(3.6-11.1) 
6.2           
(2.8-11) 
6.7          
(3.8-11.3) 
6.1          
(2.9-10.4) 
8.6        
 (3.9-12.1) 
Age at MTX 
start 
9.6         
(4.8-13.9) 
9.7             
(5.9-13.8) 
9.3            
(4.1-13.3) 
10.4           
(6.3-14) 
8.5            
(4.8-13) 
11.4         
(6.8-14.5) 
 
Disease 
duration before 
MTX start 
0.8           
(0.3-2.7) 
1            
(0.4-3.2) 
0.7           
(0.3-2.9) 
1.4          
(0.5-3.3) 
0.6            
(0.3-2.3) 
1.3             
(0.5-3.4) 
 
Physician’s 
global 
assessment of 
disease activity 
45.5            
(25-67) 
33           
(22-55) 
40               
(25-65) 
29             
(20-52.7) 
45               
(26-67) 
30          
 (20-55) 
Parents 
evaluation of 
overall well- 
being 
44          
(20-62) 
35              
(15-55) 
42               
(19-60.25) 
31               
(11-58) 
42           
(20-59) 
31.5             
(10-57) 
Parents 
evaluation of 
Child’s pain 
40          
(15-62) 
33.5            
(10-57) 
39.5            
(15-58.7) 
32           
(13-55) 
40            
(17.2-58.7) 
29.5               
(5-56.25) 
 
CHAQ 
0.5           
(0.12-0.87) 
0.3              
(0-0.7) 
0.5            
(0.12-0.8) 
0.25              
(0-0.8) 
0.5            
(0.12-0.9) 
0.25            
(0-0.75) 
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Table   18:  Articular characteristics at start of treatment  in ACR70  responders and 
ACR70 non-responders. Data are in median (first to third quartile) 
 
 
 
 
Table 19: JIA categories in patients divided into PedACR70 responders and non-
responders at month 3, 6 and 12 
 
 
 
 
 
 
Character PedACR 70 At 3 months 
No of patient   731 
PedACR 70 At 6 months  
No of patient    649  
PedACR 70 At 12 months 
No. of patient   707 
 Responder 
315(43.1 %)  
Non 
responder 
416(56.9 %) 
Responder 
368 (56.7 %) 
Non 
responder 
281(43.3 %) 
Responder 
466(65.9 %) 
Non 
responder 
241(34.1 %) 
No. of 
active 
joints 
 4 (2-8)  3 (1-5)      4 (2-7.25) 
 
3 (1-5) 4 (2-8) 2 (1-5) 
No of 
tender 
joints  
3 (2-7.5) 3 (1-6) 3 (2-7) 
 
2 (1-6) 3 (2-7) 2 (1-6) 
No. of 
swollen 
joints 
3 (1-6.5) 2 ( 1-5) 3 (2-7) 2 (0-4) 3 (2-7) 2 (0-5) 
No. of 
joints with  
LOM 
4 (2-8) 3 (1-5) 4 (2-7.25) 
 
3 (1-5) 4 (2-8) 2  (1-5) 
Duration of 
MS 
 
30 (20-60) 30 (15-60) 30 (20-60) 
 
30 (10-60) 30 (20-60) 30 (15-60) 
 
JIA categories 
 
PedACR 70 at 3 months   
No. of patients 731 
PedACR 70 at 6  months  
No. of patients   649 
 
PedACR 70 at 12 months 
No. of patients  707 
 Responder 
315 
(43.1 %) 
Non 
responder 
416(56.9 %) 
Responder 
368 
(56.7 %) 
Non 
responder 
281(43.3 %) 
Responder 
466   
(65.9 %) 
Non 
responder 
241(34.1 %) 
 Systemic 
onset JIA 
14        
 (56 %) 
11       
(44 %) 
15       
(75 %) 
5         
(25 %) 
13     
(76.5 %) 
4      
(23.5 %) 
Seronegative 
Polyarthitis 
82          
(41 %) 
118     
(59 %) 
103  
(61.3 %) 
65    
(38.7 %) 
135    
(70.3 %) 
57     
(29.7 %) 
 Seropositive 
Polyarthritis 
15     
(68.2 %) 
7      
(31.8 %) 
15     
(68.2 %) 
7       
(31.8 %)       
16      
(69.6 %) 
7       
(30.4 %) 
Persistent  
Oligoarthitis 
84   
(40.6 %) 
123  
(59.4 %) 
113  
(59.8 %) 
76     
(40.2 %) 
145    
(67.4 %) 
70     
(32.6 %) 
 Extended  
Oligoarthritis 
50    
(52.1 %) 
46  
(47.9 %) 
46    
(54.1 %) 
39     
(45.9 %) 
63    
(66.3 %) 
32     
(33.7 %) 
 ERA 
 
35    
(38.5 %) 
56  
(61.5 %) 
39     
(45.3 %) 
47    
(54.7 %)               
52      
(61.9 %) 
32     
(38.1 %) 
JPsA 
  
29    
(40.3 %) 
43 
(59.7 %) 
32     
(46.4 %) 
37     
(53.6 %) 
34      
(50.7 %) 
33     
(49.3 %) 
unclassified 
JIA 
6       
(33.3 %) 
12  
(66.7 %) 
5           
(50 %) 
5          
(50 %) 
8       
(57.1 %)   
6       
(42.9 %)    
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4.4  Bivariate analysis 
4.4.1  Minimal response (PedACR 30) 
 
Tables No. 20, 21 and 22 show the demographic, laboratory, clinical and articular 
parameters of the patients at month 3, 6 and 12. The comparative analysis has 
been done to evaluate the determinants of minimal response (PedACR 30) by 
using correlation analysis. 
 
 
 
 
 
Table  20:  Evaluation of the determinants of minimal response (PedACR30) to MTX  by 
Using Pearson’s correlation   
 
 
 
 
 
 
Determinants 
of  response 
 
PedACR 30 at 3 months 
 
 
PedACR 30 at 6 months 
 
PedACR 30 at 12 months 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
 Female 
gender 
 
-0.019 
 
0.609 
 
-0.009 
 
0.81 
 
0.01 
 
0.8 
 
ANA positive 
  
0.006 
 
0.864 
  
0.096 
 
0.017 
  
0.084 
 
0..027 
 
HLA B27 
positive 
  
 
-0.039 
 
0.326 
 
-0.046 
 
0.279 
 
-0.041 
 
0.305 
 
Concomitant 
use of NSAID 
 
 
0.123 
 
0.001 
 
0.089 
 
0.024 
 
0.092 
 
0.014 
 
Concomitant 
use of 
corticosteroid 
 
0.044 
 
0.234 
 
-0.008 
 
0.837 
 
0.027 
 
0.467 
 
Presence of 
morning 
stiffness  
 
0.168 
 
0.000 
 
0.101 
 
0.01 
 
0.128 
 
0.001 
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Table  21: Evaluation of the determinants of minimal response (PedACR30) to MTX  by 
Using Spearman-correlation. 
 
 
 
 
 
 
 
 
Determinants of 
response 
  
PedACR 30 at 3 months 
  
PedACR 30 at 6 months 
  
PedACR 30 at 12 months 
  
correlation 
coefficient 
 
significance 
 
correlation 
coefficient 
 
significance 
 
correlation 
coefficient 
 
Significance 
 
Age at onset of 
disease 
 
 
0.003 
 
0.94 
 
-0.102 
 
0.009 
 
-0.111 
 
0.003 
  
Age at MTX start 
 
 
 
-0.02 
 
0.588 
 
-0.161 
 
0.000 
 
-0.155 
 
0.000 
Disease duration 
before MTX start 
 
 
-0.072 
 
0.053 
 
-0.162 
 
0.000 
 
-0.118 
 
0.002 
Diagnosis  
(JIA category)) 
 
-0.054 
 
0.148 
 
-0.013 
 
0.741 
 
-0.01 
 
0.791 
 
 No. of  Tender 
joints 
 
 
0.196 
 
0.000 
 
0.139 
 
0.000 
 
0.138 
 
0.000 
No. of swollen 
joints 
 
 
0.295 
 
0.000 
 
0.263 
 
0.000 
 
0.223 
 
0.000 
No. of active 
joints 
 
 
 
0.325 
 
0.000 
 
0.285 
 
0.000 
 
0.238 
 
0.000 
No. of joints with 
LOM 
 
 
0.256 
 
0.000 
 
0.195 
 
0.000 
 
0.239 
 
0.000 
Duration of 
morning stiffness 
 
 
0.101 
 
0.041 
 
0.042 
 
0.416 
 
-0.042 
 
0.4 
 
CHAQ 
 
 
 
0.145 
 
0.000 
 
0.087 
 
0.026 
 
0.166 
 
0.000 
Parent’s 
evaluation of  
overall wellbeing 
 
0.186 
 
0.000 
 
0.098 
 
0.016 
 
0.103 
 
0.008 
Physician’s 
global 
assessment of 
disease activity 
 
0.163 
 
0.000 
 
0.204 
 
0.000 
 
0.133 
 
0.000 
Parent’s 
evaluation of 
child’s pain 
 
0.116 
 
0.003 
 
0.048 
 
0.24 
 
0.064 
 
0.101 
 
ESR 
 
 
 
0.147 
 
0.000 
 
0.182 
 
0.000 
 
0.201 
 
0.000 
 
CRP 
 
 
 
0.074 
 
0.051 
 
0.108 
 
0.007 
 
0.154 
 
0.000 
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Table 22: Evaluation of the determinants of minimal response (PedACR30) to MTX 
according to different JIA categories by using Pearson’s correlation.   
 
 
 
          
Female gender is in tendency of value, but statistically not significant. Females 
are as likely as males to reach a minimal response of PedACR 30. The lack of 
ANA tends to be a marker for poor response. HLA B27 is not indicative for a poor 
response. Treatment with corticosteroid statistically is not of value, while use of 
NSAID is a positive predictor for minimal response. A higher number of active 
joints as well as a higher number of joints with limitation of movement, swollen 
and tender joints as well as presence of morning stiffness are positive predictors 
for PedACR 30  response, also a higher CHAQ score was a positive predictor to 
reach minimal response. A higher age at onset of disease, higher age at start of 
MTX, longer disease  duration before starting  MTX  and  a lower  levels  of  ESR 
and CRP,  as  well  as  low score  of  physician’s global  assessment  of  disease  
JIA 
categories 
PedACR 30 at 3 months 
 
PedACR 30 at 6 months PedACR 30 at 12 
months 
Pearson’s 
correlation 
Significance Pearson’s 
correlation 
Significance Pearson’s 
correlation 
Significance 
Systemic 
onset JIA 
 
0.03 0.425 0.04 0.314 -0.003 0.94 
Seronegative 
Polyarthitis 
 
0.052 0.157 0.075 0.056 0.056 0.138 
Seropositive 
Polyarthritis 
 
0.018 0.618 0.046 0.242 0.019 0.61 
Persistent  
Oligoarthitis 
 
-0.009 0.802 -0.007 0.866 0.004 0.915 
Extended  
Oligoarthritis 
 
-0.032 0.384 0.057 0.148 0.023 0.533 
ERA 
 
 
-0.044 0.233 -0.128 0.001 -0.055 0.142 
JPsA 
 
 
-0.008 0.824 -0.079 0.045 -0.072 0.054 
unclassified 
JIA 
0,001 0.971 0.028 0.48 0.01 0.787 
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activity  are  negative  predictors  to  reach  minimal  response.  Most  of  the  last 
predictors show a strong significance, while the presence of ANA and 
concomitant use of NSAID show a weak significance. JIA categories in general 
has no effect on reaching minimal response, the exception was for enthesitis 
related arthritis and psoriasis associated arthritis categories, both of them were at 
month 6 negative predictors to reach PedACR 30. While duration of morning 
stiffness and the parents evaluation of  child’s pain have no effect on reaching 
minimal response after  month 3. 
4.4.2  Strong response (PedACR 70) 
 
Tables No. 23, 24 and 25 show the demographic, laboratory, clinical and articular 
parameters of the patients at month 3, 6 and 12. The comparative analysis has 
been done to evaluate the determinants of strong response (PedACR 70) by 
using correlation analysis. 
 
Table 23: Evaluation of the determinants of strong response (PedACR70) to MTX by 
using Pearson’s correlation.   
 
 
 
 
 
Determinants 
of  response 
 
PedACR 70 at 3 months 
 
 
PedACR 70 at 6 months 
 
PedACR 70 at 12 months 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
Female gender 
 
 
 
-0.067 
 
 
0.068 
 
-0.028 
 
0.475 
 
-0.032 
 
0.393 
 
ANA positive 
 
 
 
-0.017  
 
0.652 
  
0.06 
 
0.133 
  
0.045 
 
0.237 
 
HLA B27 
positive 
  
 
-0.011 
 
0.772 
 
-0.01 
 
0.808 
 
0.007 
 
0.854 
 
Concomitant 
use of NSAID 
 
 
0.072 
 
0.051 
 
0.037 
 
0.347 
 
0.07 
 
0.062 
 
Concomitant 
use of 
corticosteroid 
 
0.07 
 
0.057 
 
0.019 
 
0.633 
 
0.06 
 
0.113 
 
Presence of 
morning 
stiffness 
 
0.035 
 
0.341 
 
0.057 
 
0.145 
 
0.14 
 
0.000 
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Table 24: Evaluation of the determinants of strong response (PedACR70) to MTX 
according to different JIA categories by using Pearson’s correlation. 
 
 
 
 
 
 
 
 
JIA  
categories 
 
PedACR 70 at 3 months 
 
 
PedACR 70 at 6 months 
 
PedACR 70 at 12 months 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
Pearson’s 
correlation 
 
Significance 
 
Systemic 
onset JIA 
 
0.049 
 
0.185 
 
0.066 
 
0.094 
 
0.035 
 
0.353 
 
Seronegative 
Polyarthitis 
 
-0.026 
 
0.484 
 
0.055 
 
0.162 
 
0.057 
 
0.132 
 
Seropositive 
Polyarthritis 
 
0.089 
 
0.016 
 
0.043 
 
0.27 
 
0.014 
 
0.708 
 
Persistent  
Oligoarthitis 
 
-0.032 
 
0.389 
 
0.04 
 
0.31 
 
0.021 
 
0.571 
 
Extended  
Oligoarthritis 
 
0.071 
 
0.056 
 
-0.02 
 
0.607 
 
0.003 
 
0.929 
 
ERA 
 
 
 
-0.035 
 
0.341 
 
-0.09 
 
0.023 
 
-0.031 
 
0.41 
 
JPsA 
 
 
 
-0.019 
 
0.612 
 
-0.072 
 
0.067 
 
-0.104 
 
0.006 
 
unclassified 
JIA 
 
-0.031 
 
0.398 
 
-0.017 
 
0.667 
 
-0.026 
 
0.485 
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Table 25: Evaluation of the determinants of strong response (PedACR70) to MTX by 
Using Spearman-correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
Determinants of 
response 
 PedACR 70 at 3 months  PedACR 70 at 6 months  PedACR 70 at 12 months 
 correlation 
coefficient 
significance correlation 
coefficient 
significance correlation 
coefficient 
Significance 
Age at onset of 
disease 
 
 
-0,022 
 
0,551 
 
-0,061 
 
0,12 
 
-0,114 
 
0,003 
 Age at MTX start 
 
 
 
-0,072 
 
0,051 
 
-0,108 
 
0,006 
 
-0,165 
 
0,000 
Disease duration 
before MTX start 
 
 
-0,094 
 
0,011 
 
-0,177 
 
0,000 
 
-0,164 
 
0,000 
Diagnosis  
(JIA category) 
 
0,016 
 
0,657 
 
-0,04 
 
0,315 
 
-0,028 
 
0,452 
 
 No. of  Tender 
joints 
 
 
0,106 
 
0,004 
 
0,141 
 
0,000 
 
0,113 
 
0,003 
No. of swollen 
joints 
 
 
0,116 
 
0,002 
 
0,229 
 
0,000 
 
0,223 
 
0,000 
No. of active 
joints 
 
 
 
0,146 
 
0,000 
 
0,223 
 
0,000 
 
0,221 
 
0,000 
No. of joints with 
LOM 
 
 
0,158 
 
0,000 
 
0,188 
 
0,000 
 
0,208 
 
0,000 
Duration of 
morning stiffness 
 
 
0,042 
 
0,399 
 
0,089 
 
0,088 
 
0,045 
 
0,367 
CHAQ 
 
 
 
0,074 
 
0,047 
 
0,098 
 
0,013 
 
0,16 
 
0,000 
Parent’s 
evaluation of 
overall wellbeing 
 
0,116 
 
0,002 
 
0,111 
 
0,006 
 
0,109 
 
0,005 
Physician’s 
global 
assessment of 
disease activity 
 
0,154 
 
0,000 
 
0,187 
 
0,000 
 
0,184 
 
0,000 
Parent’s 
evaluation of 
child’s pain 
 
0,066 
 
0,086 
 
0,06 
 
0,141 
 
0,117 
 
0,003 
ESR 
 
 
 
0,107 
 
0,005 
 
0,199 
 
0,000 
 
0,213 
 
0,000 
CRP 
 
 
 
0,057 
 
0,131 
 
0,177 
 
0,000 
 
0,209 
 
0,000 
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At month 3, the number of strong responders (according to PedACR70 criteria) 
was 315 patients (43.1 %), while at month 6, the number of strong responders 
was 368 patients (56.7 %), and at month 12, the number of strong responders 
was 466 patients (65.9 %).  This increase in the number of responders after 
month three, suggests  that the  three months data may be affected by the delay 
of clinical response achieved by MTX  treatment. Statistically female gender  has 
no effect on reaching a strong response (PedACR70), as well as lack of ANA, 
HLA B27,  concomitant use of NSAID and corticosteroid have no significant effect 
on reaching strong response (PedACR70) to MTX. Poor response according to 
PedACR 70 criteria was associated with a longer disease duration before starting 
MTX, a lower score of physician’s global assessment of disease activity, a lower 
score of CHAQ, a lower score of parent’s evaluation of child’s overall well-being 
as well as lower values of ESR and CRP. The significance of these        
predictors was very strong at month 12 (p value < 0,001). A higher age at start of           
MTX  after 6 months as well as a higher age at onset of disease   after 12 months 
from the beginning of MTX therapy considerable also as poor predictors                                       
(p value= 0,006 and 0,003 respectively). Enthesitis related arthritis at month 6 
and psoriasis associated arthritis at month 12 were negative predictors to reach 
strong response (p value=0,023 and 0,006 respectively), while seropositive 
polyarthritis at month 3 (p value= 0,016) was positive predictor to reach strong 
response (PedACR 70), but in general the diagnosis of different JIA categories 
was not significant. Strong response according to PedACR 70 criteria was 
associated with a higher number of  active joints, tender joints, swollen joints and 
joints with limitation of movement and presence of morning stiffness after month 
12, while duration of morning stiffness  has no effect on reaching strong response 
(PedACR70) to MTX. 
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4.5  Multivariate Analysis 
Multivariate logistic regression analysis has been done with all variables that 
were significantly associated with PedACR 30 or 70 poor response at months 3, 
6 and 12. Tables No.  26, 27 and 28 shows Logistic regression model obtained 
from the evaluations of the determinants of  response to MTX according PedACR 
30 at month 3, 6 and 12.                                                                                           
The predictors accuracy were evaluated by ROC (receiver operating chara- 
cteristic) curve analysis. The best area under the ROC curve (AUC) for PedACR 
30 was observed at month 3 (AUC= 0.734 , specificity= 3.9 % and sensitivity= 
99.8 %), while the best  area under  the  ROC curve (AUC) for the PedACR 70 
was observed at month12 (AUC= 0.694, specificity= 29 % and sensitivity= 90 %). 
                                                                                                      
Predictors of poor response  according to PedACR 30 criteria at month 3 were a 
higher  number  of   tender  joints  (OR=0.92),  a lower  number  of  active  joints 
(OR=1.26) and a lower score  of  parent’s  evaluation of  over  well-being  (OR = 
1.06).     
                         
                         
                         
                         
          
 
 
                    
Table  26: Determinants of response according to PedACR 30 at month 3  
 
 
P Value  OR (95% CI)   Determinants of  response  
0.003  0.925 (0.878-0.974)  Number of tender joints  
0.000  1.262 (1.164-1.368)  Number of active joints  
0.000  1.069 (1.008-1.025)  Parents evaluation of overall 
well-being  
 0.734 Area under ROC curve of the 
 model 
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Figure  12: ROC- Curve  for PedACR30 at month 3, AUC= 0.734, specificity=10.7 %, 
sensitivity= 98.9 %, accuracy= 84 %           
                                                                                               
At month 6  the  predictors of  poor response  according   to  PedACR 30  were a 
disease  duration  more  than  1 year  (OR= 0.48)   a higher   age  at   MTX  start 
(OR=0.91),  a lower  number   of   active  joints,  a  lower   score  of   Physician’s 
global  assessment   of  disease  activity (OR=1.01), while   concomitant   use  of 
NSAID  was  a  positive  predictor  to  reach   PedACR 30 (OR=1.85).                   
                                                                                                      
 
 
 
 
 
- 63 - 
 
     
   
 
 
 
 
 
 
 
 
Table 27: Determinants of response according to PedACR 30 at month 6    
 
                                                                              
 
Figure 13: ROC-Curve  for PedACR 30 at month 6, AUC= 0.726, specificity= 19.1 %, 
sensitivity= 97.5 %, accuracy= 83.6 %                                                                                
     
 
 
P Value  OR (95% CI)  Determinants of response  
0.002 0.481 (0.304-0.762) Disease duration > 1 year 
0.000  0.91 (0.87-0.96)  Age at MTX start  
0.001  1.11 (1.05-1.18)  Number of active joints  
0.004  1.02 (1.01-1.03)  Physician’s global 
assessment of disease activity  
0.048  1.85 (1.01-3.39)  Concomitant use of NSAID  
 
0.726 Area under ROC curve of the  
model 
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At month 12 predictors of poor response according to PedACR 30 were a 
disease duration more than 1 year (OR= 0.64), a higher age at MTX start  
(OR=0.9), a lower number of  joints  with limitation of motion (OR=1.11),  a  lower 
ESR  values  (OR=1.01), while concomitant use  of NSAIDs was a good predictor 
to reach PedACR 30 (OR=2.1).                                                                                
 
                        
                        
                        
                        
                        
        
 
 
 
 
Table  28: Determinants of response according to PedACR 30 at month12 
 
 
 
 
 
 
 
 
 
 
 
 
 
P Value  OR (95% CI)   Determinants of response  
0.047 0.643 (0.416-0.994) Disease duration > 1 year 
0.000  0.91 (0.86-0.95)  Age at MTX start  
0.000  1.11 (1.05-1.18)  Number of joints with LOM  
0.028  1.02 (1.002-1.029)  ESR  
0.021  2.1 (1.12-3.97)  Concomitant use of NSAID  
 
0.716 Area under ROC curve of the  
model 
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Figure  14:  ROC-Curve  for  PedACR 30 at  month 12, AUC= 0.716,  specificity= 3.6 %, 
sensitivity= 99.6 %, accuracy= 84.4 % 
 
Tables No. 29, 30 and 31 shows Logistic regression model obtained from the 
evaluations of the determinants of response to MTX according PedACR 70 at 
month 3, 6 and 12.                                                                                                    
According to the PedACR 70 criteria, the baseline determinants for poor MTX 
response at month 3 were a lower number of joints with limitation of motion 
(OR=1.03) and a lower score of Physician’s global assessment of disease activity 
(OR=1.01).                                                                                                                 
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Table  29:  Determinants of response according to PedACR 70 at month 3 
 
 
Figure  15: ROC-Curve  for PedACR 70 at month 3, AUC=0.606, specificity=77.4 %, 
sensitivity=35 %, accuracy=58.7 %         
 
 
 
                                                                        
P Value  OR (95% CI)   Determinants of  response  
0.004  1.038 (1.012-1.064)  Number of joints with 
limitation of motion  
0.004  1.01 (1.003-1.016)  Physician’s global 
assessment of disease 
activity                      
 
0.606 Area under ROC curve of the 
 model 
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 At 6 months the determinants of poor response according  PedACR 70  were      
 a disease  duration  more  than 1 year (OR=0.54), a higher  age at MTX start  
(OR=0.95), a lower  number  of  swollen  joints (OR=1.06)  and  a lower score      
of a Physician’s global assessment of disease activity (OR=1.01).                         
  
. 
                        
                        
                        
                        
                
 
Table  30:  Determinants of response according to PedACR 70 at month 6  
 
 
Figure  16: ROC-Curve  for PedACR70 at month 6, AUC= 0.646, specificity= 46 %, sensitivity= 
78.2 %, accuracy= 64.3 %                                                                              
 
        
 
P Value  OR (95% CI)   Determinants of response  
0.000 0.546 (0.419-0.711) Disease duration > 1 year 
0.018  0.959 (0.926-0.993)  Age at MTX start  
0.001  1.06 (1.025-1.095)  Number of swollen joints  
0.004  1.011 (1.003-1.018)  Physician’s global assessment of 
disease activity  
 0.646 Area under ROC curve of the  
model 
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At  12  months  the  determinants  of  poor  response  according  PedACR 70       
were  in addition  to  a higher  age  at  MTX start (OR= 0.92),  also  a disease      
duration more  than 1  year  (OR= 0.54)  a higher   number  of   tender   joints  
(OR=  0.93), a lower  number  of  active  joints  (OR= 1.09), a lower  score  of      
 a Parent’s evaluation of  child’s  pain (OR= 1.01), a lower value  of CRP  (OR     
= 1.01) , while  a  presence of  morning   stiffness   was   a good   predictor  to    
reach strong response (PedACR 70) at month 12  (OR= 1.59).                              
                                                                                        
                                         
             
 
 
  
 
 
 
 
 
 
Table 31: Determinants of response according to PedACR 70 at month 12  
 
 
 
 
 
 
P Value  OR (95% CI)   Determinants of  response  
0.001 0.544 (0.385-0.77) Disease duration > 1 year 
0.000  0.926 (0.89-0.964)  Age at MTX start  
0.004  0.936 (0.895-0.98)  Number of tender  joints  
0.000  1.096 (1.042-1.153)  Number of active joints  
0.037  1.008 (1.000-0.015)  Parent’s evaluation of child’s 
pain  
0.018 1.011 (1.002-1.02) CRP  
0.016 1.59 (1.1-2.33) Presence of morning stiffness  
 
0.694 Area under ROC curve of the 
 model 
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Figure  17: ROC-Curve  for PedACR70 at month 12, AUC=0.694, specificity= 33.2 %, 
sensitivity= 91.5 %, accuracy= 71.8 %     
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5.  Discussion 
The major findings of this study were that a higher number of joints with limitation 
of motion and a higher score of physician’s global assessment of disease  activity 
at baseline were predictors for reaching a strong response (PedACR 70) after 3 
months of treatment with MTX.  
At month 6, a shorter disease duration, a lower age at start of MTX, a higher 
number of swollen joints and a higher score of physician’s global assessment of 
diseases activity were associated with a higher likelihood of marked improvement 
(PedACR 70).  
At month 12 the likelihood of a marked improvement according to the PedACR70 
criteria was associated  with a shorter disease duration,  a lower age at  start of  
MTX, a lower number of tender joints, a higher CRP value, a higher number of 
active joints, a higher score of  parent’s evaluation of pain and  the presence of  
morning stiffness.  
The aim  of  modern treatment for  juvenile idiopathic arthritis  is  the rapid  induc- 
tion  of disease  control, to prevent  joint  damage, to maximise physical  function, 
and promoting normal growth and  normal  lifestyle  for  the patients, as well as to 
achieve  these  goals  with  minimal  risk of  side  effects,  the  recent  concept  of 
 juvenile  idiopathic  arthritis  management   suggests  that  the  early  aggressive 
 intervention  may  buy  long  term disease suppression (Albers et al., 2009; Vilca 
et al., 2010).                               
The  aim  of  this  retrospective  study  on  915  patients  with  juvenile  idiopathic 
arthritis, who were treated with MTX for  at least 3 months, was  to determine the 
predictors of response to MTX.                                                                                 
Despite the presence  of considerable variation in  the clinical  response  to  MTX 
among  patients, and  the  availability  of  several  new  agents  for the  treatment 
of  JIA, methotrexate remains  the most common second  line  therapeutic  agent 
used in treatment of JIA worldwide  because of  both cost and experience (Miller 
and Cassidy, 2007).      
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The identification of predictors of response is helpful to develop recommenda-
tions for MTX use, especially starting of MTX as well as further continuation or 
early discontinuation and starting use of biological drugs, and the aim of this 
study is to determine whether demographic, clinical, articular and laboratory 
variables at baseline and during follow up at months 3, 6 and 12  predict MTX 
response in patients with juvenile idiopathic arthritis.                                               
In  this  study,  the  cohort  of  patients  was  collected  from  the  German  BIKER 
Registry, founded  in  2001. Since  2005, patients  newly  started with  MTX, were 
included  into the registry, data of patients admitted to the registry until December 
31, 2010 were  used for this analysis.                                                                       
The total number of  patients in  this  retrospective study  was  915  patients, who 
belong to all categories of JIA, and treated with MTX at least for 3 months,     
while  the patients who currently receive or have been received biologics were 
excluded,  the females  represent  68.5 % of  the  sample (627 patients), while 
the males represent 31.5 % of the sample (288 patients).                                        
The analysis  of  demographic,  clinical,  articular  and   laboratory characteristics 
of patients was made at baseline and during follow up at months 3, 6 and 12.   
The improvement  was  assessed according to the paediatric criteria of American 
College of Rheumatology by using PedACR 30 for minimal improvement analysis 
and PedACR 70 for strong improvement analysis.                                                
The PedACR 30  was initially  designed  to distinguish  between  active treatment 
and  placebo, it  was  a significant  step  towards creating  standardized  outcome 
measures in paediatric rheumatology, these  measures primarily   assess relative 
efficacy within the  context  of  clinical  trials.                                                            
These measures are of less utility in quantifying response, tracking patient   
progress longitudinally and describing an individual’s disease state at specific 
moment (Ringold and  Wallace, 2007).                                                                     
At month 3, 165  patients (22.6 %) were  non responders  according  to  PedACR 
30, poor  response  to  MTX  according  to  PedACR 30  criteria at  month  3  was  
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associated   with  a higher  number  of   tender  joints  (OR=0.92 and  p=0.003), a 
lower   number  of  active  joints (OR=1.26 and  p<0.001)  und   a lower  score  of 
parent´s evaluation of overall  well-being (OR=1.06 and p<0.001).                          
While at month 6, 121 of patients (18.6 %) were PedACR 30 non responders, the 
poor response was associated with disease duration > 1 year (OR= 0.48 and p= 
0.002), a higher age at MTX start (OR=0.91 and P<0.001), a lower  number of 
active joints (OR=1.11 and p=0.001), in addition to a lower score of physician’s 
global assessment of disease activity (OR=1.01 and p=0.004), while concomitant 
use of NSAID was a positive predictor to reach PedACR 30 (OR=1.85 and 
p=0.048).                                                                                                                   
The  number of patients who were PedACR 30 non responders at month 12  was 
120 (16.9 %), the poor response according to PedACR 30 criteria at month 12 
was associated with a disease duration < 1 year ( OR= 0.64 and p= 0.047), a 
higher  age at MTX start  (OR=0.9 and p<0.001), a lower number of joints  with 
limitation of motion (OR=1.11 and p<0.001) and a lower values of ESR (OR=1.02 
and p=0.028), while concomitant use of NSAIDs was a positive predictor 
(OR=2.1 and p=0.021).                                                                                             
Although female gender was in tendency of  value  to reach  minimal  response   
(PedACR 30), but statistically not significant,  females were as likely as males to 
reach minimal response.  The lack  of  ANA, as well as enthesitis  related arthritis 
and  psoriatic  associated arthritis  subtypes, tend to be a poor response markers 
to reach PedACR 30, but statistically were not significant.                                       
However, there is argument that only improvement in disease activity above Ped- 
ACR 70 predicts a more favourable long term outcome and reflect a major clinical 
response to treatment (Pincus et al., 2004; Vilca et al., 2010).                                 
Previous studies have shown conflicting results regarding predictors of     
response to MTX,  in three previous studies, the results  indicate  a different         
effect of MTX according  to the  type  of  JIA, Halle  and  Prieur  found  that  the 
systemic form seemed  less  responsiveness  than  ANA  positive  form  with  
polyarticular  course (Halle and Prieur, 1991), while Woo, et al, found  that  MTX  
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 is an effective treatment for both extended oligoarthritis and systemic JIA ( Woo 
et al., 2000), as well as Ravelli, et al, concluded that  the extended oligoarthicular 
subtype is the best predictor of methotrexate efficacy (Ravelli et al., 1999).            
However  the analysis of the PRINTO methotrexate trial has been found  that the 
frequency of JIA categories was comparable between responders and non- 
responders (Vilca  et al., 2010).                                                                                
The  present study  confirm  the  observations  of  PRINTO  study   regarding  JIA 
categories, in  multivariate analysis we found  that, the different  JIA  categories  
not statistically significant to predict the response to MTX (according  to  PedACR 
70 criteria), although the bivariate analysis (using  Pearson’s correlation method) 
suggested  that  seropositive polyarthritis  category  at  month 3,  was associated 
with greater likelihood to reach early response (p=0.016), while  enthesitis related 
arthritis  at  month 6,  was  associated   with   poor  response  (p=0.023),  as  well 
as psoriatic  associated  arthritis subtype at month 12, was  also  associated  with 
greater likelihood of poor response (p=0.006).                                                         
The  present  study shows that  according  to PedACR 70  criteria, the  number of 
responders at month 3 was  315 patients (43.1 %), while at month 6, the  number 
of  responders  increased  to 368 patients (56.7 %), and  at  month 12  increased 
to 466 patients (65.9 %).                                                                                           
Theses increasing in the number of responders through the progressing in 
course of  treatment, suggest that the three months data may be affected by the 
delay of clinical response achieved by MTX treatment, these findings are in line 
with common view that the maximum therapeutic effect usually becomes  
apparent 4 to 6 months after the beginning of treatment (Ravelli and Martini, 
2000).                                                                                                                        
In this study, at month 3, a significant relationship was found between a higher 
number of joints with limitation of motion (OR=1,03  p=0,004), as well as a higher 
score of Physician’s global assessment of overall disease activity (OR=1,01  
p=0,004) and strong response to MTX according to PedACR 70 criteria.                
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The presence of both predictors as  parts  of   ACR pediatric  criteria of  response 
could only hardly explain the relationship, since the improvement of  these criteria 
participates  to  the PedACR  score, a  higher  values  at  initiation of  therapy are 
associated with a higher likelihood of improvement.                                                 
Furthermore this study shows that the Physician’s  global  assessment of overall 
disease activity as predictor of response is significant at month 3 and 6, but  at  
month 12 not significant, this suggest that patients with lower score of  
Physician’s global assessment of overall disease activity  need  longer  duration 
to reach   PedACR 70 response.                                                                              
At month 6, the patients with a higher number of swollen joints at baseline,  were 
associated  with  a greater likelihood  of  strong  response  to  MTX (OR=1.06 p= 
0.001).                 
We had not expected, nor can we explained the relationship between age at MTX 
start and the response to MTX. During this study we found that  a higher age at 
MTX start was associated with a poorer response, with significant values at 
month 6 (OR=0.95  p=0.018) and month 12 (OR=0.92  p<0.001).                           
Previously an association between the weight of patient and the response has 
been observed. In a multicenter, randomized, controlled trial, Silverman et al 
found  that weight was significantly associated with a response and influenced 
treatment effect, and the patients weighing less than 20 kg had the greatest 
improvement (Silverman et al., 2005).                                                                      
Because the mean age at MTX start in seropositive polyarthritis and enthesitis 
related arthritis categories (12.4 and 12.9 years respectively) were higher  than  
in other categories (for systemic onset JIA  6.9 years, in persistent oligoarthritis  
8.3 years,  in extended oligoarthritis   8.6 years, and in seronegative polyarthritis 
category was 9.4 years), to confirm our finding, the analysis has been repeated 
for age at MTX start without seropositive polyarthritis and enthesitis related 
arthritis patients, the analysis shown again a significant values at month 6 
(OR=0.921 p=0.001), and at month 12 (OR=0.906 p<0.001).                                  
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These findings  confirm that, a higher  age  at  MTX start  is  a poor  predictor  for 
reaching PedACR 70 in different  JIA categories, as well  as  suggest  that 
patients with a higher age  at  MTX  start, and  who  are PedACR 70 non  
responder  at month 6, are highly recommended candidates for treatment with 
biologics.                                                                                                                   
At  month 12, we  found  that, the presence  of  morning  stiffness  at  baseline  is 
a positive predictor  to  reach  PedACR 70  (OR=1.59  p=0.016), furthermore  our 
study  shows that  patients with  a higher  number  of  active joints (OR=1.09   p< 
0.001),  a higher  score of  parent’s  evaluation  of child’s  pain  (OR=1.01 p= 
0.037) and a higher CRP level at baseline (OR=1.01 p=0.018) were associated 
with greater likelihood to reach PedACR 70.                                                            
The presence  of  the  number  of  active  joints as  a part  of  PedACR  set of 
improvement could hardly explain the relationship, which most likely is due to  the 
anti-inflammatory mechanism of action of MTX. This may also explain the  
relationship   between  reaching  of  strong  response  and   the number of 
activejoints  as  well as the other activity parameters such as CRP level  and  the 
 pain, which considered as one  of  the symptoms of inflammation, which was  in 
the present  study  assessed by  the  patient  or parents global assessment of 
pain.                                                                                                                          
In contrast, a higher number of tender joints was a predictor of poor response to 
MTX  at month 12, (OR=0.93  p=0.004). The significant relationship between the 
number of tender joints and reaching a PedACR 70 response, can be explained 
by the indirect effect of presence of tenderness or pain on the components of 
PedACR criteria, not only on physician’s global assessment score and Parent’s 
evaluation of overall well-being, but also on CHAQ. The CHAQ comprises two 
indices, the first is the disability index, and the other is discomfort index which is 
determined by  the presence of pain measured by a 100 mm analogue scale 
(Duffy, 2007).                                                                                                            
This study shows that, female gender statistically had no effect on reaching          
a strong response (PedACR 70). Disease duration before MTX start was              
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significantly associated with  PedACR 70 response in  bivariate analysis,  but  in 
general the disease duration as a variable was not significant in multivariate 
analysis, may be because it was highly collinear with the age at MTX start. After 
repeating multivariate analysis without age at MTX start, the disease duration 
subclases (less or more than 1 year) had a significant effect on reaching 
PEDACR 30 and 70, we found that a shorter disease duration (< 1 year)            
was  significantly associated with  reaching a strong response (PedACR 70) at    
months 6 and 12, while disease duration (> 1 year ) was a poor predictor, this      
finding supports the results of PRINTO study and the previous clinical     
experience which suggests that the early treatment is more effective.                     
Concomitant use of NSAID was not significant  in both  bivariate and  multivariate 
analysis for reaching PedACR 70, although it was significant for reaching minimal 
response (PedACR 30), ESR and CHAQ  score  were significant  in the  bivariate 
analysis  but no longer  significant in multivariate  analysis.  
In contrast to PRINTO study of  predictors of  response to MTX the lack  of  ANA, 
as well as disease duration and CHAQ score were not significantly  predictors  
for a strong response(PedACR 70) (Vilca et al., 2010).  These  variations may  be 
due to  many  differences  between the   present study and the PRINTO  study, 
although the general design of PRINTO study was similar to the present study. 
Bivariate and logistic regression analysis was used to identify baseline predictors 
of poor response. Also the improvement was assessed according to the 
American College of Rheumatology criteria for pediatrics, by using PedACR 30 
for minimal improvement analysis and PedACR 70 for strong improvement 
analysis.                                                                                                                    
In PRINTO study  however,  the patients  with seropositive  polyarthritis, psoriatic 
arthritis and enthesitis  related arthritis  categories  were excluded from the study 
sample, while in the present study all JIA categories were included.        
An important difference between the two studies is the time of evaluation of 
improvement in both studies, while in the PRINTO study the evaluation of 
improvement  was done at month 6 only, in our study the evaluation was done at 
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 month 3, 6 and 12. Which gives advantages to the present study  and allows for 
better assessment of early response as well as the response  after moderate and 
long duration of treatment and determination  which variables could predict the 
response at these times. Another advantage of the present study is that, the 
study sample is larger than that of the PRINTO study. Our sample  included 915 
patients, while in PRINTO study the sample included 563 patients.                         
This large difference give advantage to the present study for better assessment 
of relationships between different baseline characteristics  and reaching of 
improvement, especially in the multivariate analysis. The previous differences 
may explain the differences in the results between the present study and 
PRINTO study.                                                                                                          
The diagnostic   accuracy  was  evaluated  using  receiver  operating   curve,  the 
area under the receiver characteristics curve (AUROC)  at  month 3,  for PedACR 
30  was 0.73 (sensitivity=98.9 %, specificity=10.7 %, accuracy=84 %), and for 
PedACR 70 was 0.61 (sensitivity=35 %, specificity=77.4 %, accuracy =58.7 %).    
At month 6, AUROC for PedACR 30 was 0.73  (sensitivity= 97.5 %, specificity= 
19.1 %, accuracy= 83.6 %), and for PedACR 70  was 0.65 (sensitivity = 78.2 %, 
specificity= 46 %, accuracy= 64.3 %).                                                                      
While at month 12, AUROC for PedACR 30 was 0.72 (sensitivity= 99.6 %, 
specificity= 3.6 %, accuracy= 84.4 %), and the AUROC for PedACR70 at month 
12 was 0.69 (sensitivity= 91.5 %, specificity= 33.2 %, accuracy= 71.8 %).              
These  results  can  be  accepted   especially   when   compared   with    results 
of   other  studies.   These   values   are   better   than   the   results  of   PRINTO 
study,  in  which AUROC  for PedACR 30  was  0.65, and  for  PedACR 70   was 
0.66  (Vilca et al., 2010).                                                                                           
In conclusion, we  have  found that  patients with a longer disease duration  a 
higher age at  MTX start, a lower number of score of physician’s global 
assessment of disease activity, a lower score of parent’s evaluation of child’s 
pain,  a lower  CRP, a lower  number  of  active joints, a higher number of  tender 
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 joints, a lower number of swollen joint and a lower number of joints with limitation 
of  motion  at  baseline were significantly  associated  with a greater  likelihood of 
PedACR 70  non-response, while the  presence of morning stiffness was a 
positive  predictor  to reach  PedACR 70. These  findings can be  considered as 
recommendations for the use of methotrexate in patients with  juvenile  idiopathic 
arthritis, since the presence of  these baseline determinants predict  a worse 
response  to MTX, even  after  prolongation of  exposure for up to12 months,  
thereby prompting the physicians  to start an alternative drug therapy earlier.        
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6. Summary 
Juvenile idiopathic arthritis is an umbrella term used to describe a heterogeneous 
group of disorders of unknown etiology, juvenile idiopathic arthritis is the most 
chronic rheumatic illness in children and it is responsible for short and long-term 
disability. Although methotrexate still the most common  second  line  therapeutic 
agent used  in treatment  of juvenile idiopathic arthritis worldwide and effective in 
the majority of patients, there is variation in the clinical response to methotrexate 
among  the patients. Prediction of response can prevent further exposure of  
patients to side effects of methotrexate, also save the time and start  treatment 
with biologics as soon as possible to prevent irreversible complications.                 
The  aim  of  this  study  is  to determine  whether  demographic, clinical, articular 
and  laboratory  variables  at  baseline  and  during  follow up  at  month 3, 6  and 
12 predict methotrexate response  in JIA patients, patients  data were taken from 
the  German  BIKER  Registry,  which was  founded  in 2001.   
The total number  of  patients  fulfilling  all  inclusion  and  exclusion  criteria  was 
915 patients, who  belong  to all categories of JIA, and  treated with  MTX for at 
least 3 months.  The  time  of  response  analysis   was  at  month 3, 6  and 12.  
For  assessment of  response,  the  American College of Rheumatology  pediatric 
(PedACR) criteria  was  used,  PedACR 30  for minimal response  and PedACR 
70 for strong response, and we found that, the number of PedACR 70 
responders,  were  315  patients  (43.1 %) at  month 3,  368  patients (56.7 %)  at 
month 6, and 466 patients (65.9 %) at month 12.                                                     
In  multivariate  analyse,   we  used  logistic  regression   analysis,  the   baseline 
determinants  for strong response according   to  PedACR 70  at  3 months  were 
a higher number of joints with limitation of motion (OR=1.03, p=0.004) as well  as 
a higher  score  of physician’s  global  assessment  of  disease activity (OR=1.01, 
p=0.004). At month 6 the determinants of strong response according to PedACR 
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70 were  a disease duration < 1 year (OR=1.832, p<0,001), a lower  age  at  MTX 
start  (OR=0.95 , p=0.018),  a higher   number  of   swollen joints  (OR=1.06 ,  p= 
0.001) and a higher score of  physician’s  global assessment  of  disease  activity 
(OR=1.01 , p=0.004).                                                                                                
At month 12  the determinants  of strong response  according to PedACR 70 
were a disease duration <1 year (OR=1.838, p=0.001), a lower age at 
methotrexate start (OR=0.92, p< 0.001), a lower number of tender joints  
(OR=0.93, p=0.004), a higher number of active joints  (OR=1.09, p<0.001), a 
higher score of the parent’s evaluation of   child’s pain (OR=1.01, p=0.037) and  
a higher values of CRP (OR=1.01, p=0.018), as well as the presence of morning 
stiffness is also a positive predictor to reach PedACR 70 (OR=1.59, p=0.016).       
In conclusion, the presence of morning stiffness is a positive predictor to reach 
PedACR 70, while a longer disease duration before MTX start, a higher age at 
MTX start, a lower score of  physician’s global assessment of disease activity, a 
lower score of parent’s evaluation of child’s pain, a lower CRP, a lower number of 
active joints, a higher number of tender joints, a lower number of swollen              
 joints and a lower number of joints with limitation of motion at baseline                 
 were significantly associated with a greater likelihood of PedACR 70                
non-response. The presence of these baseline determinants predict a                 
worse response to MTX and recommend to start an alternative therapy.                
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